Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/775—Apolipopeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
  • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
  • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
  • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/5123—Organic compounds, e.g. fats, sugars
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/54—Interleukins [IL]
  • C07K14/55—IL-2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/62—DNA sequences coding for fusion proteins
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
  • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
  • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Definitions

• the invention relates to the field of modified apolipoproteins that find use in the treatment or prevention of disorders. More specifically the invention relates to apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative with a targeting body. The invention further relates to lipid nanoparticles comprising the modified apolipoproteins and methods of making such. Lastly the invention relates to methods of treatment using the modified apolipoproteins or lipid nanoparticles comprising such.
• the present invention is based on the inventors’ finding that apolipoproteins, apolipoprotein derivatives, apolipoprotein mimetics or apolipoprotein mimetic derivatives may be modified to target specific cells, tissues or organs, by attaching them to a targeting body, wherein the targeting body is capable of binding a molecule on the cell surface of a target cell, and that such modified apolipoproteins can be used as a carrier for therapeutic agents, either when being used as such, meaning not as part of a lipid nanoparticle, or when as part of a lipid nanoparticle, preferably a spherical lipid nanoparticle.
• present inventors unexpectedly found that attaching a targeting body to an apolipoprotein, apolipoprotein derivative, an apolipoprotein mimetic or apolipoprotein mimetic derivative allows to easily incorporate said targeting body in a lipid nanoparticle comprising an outer layer and a core, preferably a spherical lipid nanoparticle, and to expose said targeting body to the environment surrounding said lipid nanoparticle.
• the modified apolipoprotein can be targeted to cells, tissues or organs it would otherwise not or insufficiently reach, or it could be used to reduce off-target effects.
• the invention relates to a modified apolipoprotein comprising an apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative attached to a targeting body, wherein the targeting body is a molecule capable of binding a molecule on the cell surface of a target cell.
• the invention in a second aspect relates to a lipid nanoparticle comprising an outer layer and a core, wherein the outer layer comprises:
• the core comprises at least one core component selected from: a lipid, a cationic lipid, or a polyvalent molecule.
• the invention in a third aspect relates to a lipid nanoparticle comprising an outer layer and a core, wherein the outer layer comprises:
• the core comprises a nucleic acid and a cationic or ionizable cationic lipid.
• the invention in a fourth aspect relates to a method of manufacturing a lipid nanoparticle as disclosed herein, the method comprising the steps of: a1) expressing and isolating a modified apolipoprotein as disclosed herein to obtain an isolated modified apolipoprotein; and/or a2) chemically conjugating a targeting body to an apolipoprotein or apolipoprotein mimetic to obtain a modified apolipoprotein and isolating the modified apolipoprotein; b) combining the isolated modified apolipoprotein obtained in step a1 and/or step a2 with phospholipids, sterols and optionally lipids to obtain a lipid nanoparticle.
• the invention in a fifth aspect relates to a method for producing a lipid nanoparticle, comprising the step of: a) rapid mixing of lipid components in organic solvent with a nucleic acid in an aqueous buffer to produce lipid nanoparticles, wherein the lipid components comprise a phospholipid, a sterol, a cationic lipid or ionizable cationic lipid, wherein the aqueous buffer has a pH of 5.0 or lower; and b) rapid mixing of the lipid nanoparticles with one or more modified apolipoprotein as taught herein; to produce the lipid nanoparticle at a pH between 5.5 and 8.0, preferably pH between 6.0 and 8.0.
• the invention relates to a modified apolipoprotein according to the first aspect or the lipid nanoparticle according to the second or third aspect, or the lipid nanoparticle obtained or obtainable by the method of the fourth or fifth aspect of the invention for use as a medicament.
• the invention relates to a modified apolipoprotein according to the first aspect or the lipid nanoparticle according to the second or third aspect, or the lipid nanoparticle obtained or obtainable by the method of the fourth or fifth aspect of the invention for use in the treatment or prevention of an immune related disorder such as transplantation rejection, graft-versus-host disease (GVH), atherosclerosis, infection, inflammation, auto-immunity, allergy, cancer, a genetic disorder, a metabolic disorder, a neurological disorder or tissue trauma.
• an immune related disorder such as transplantation rejection, graft-versus-host disease (GVH), atherosclerosis, infection, inflammation, auto-immunity, allergy, cancer, a genetic disorder, a metabolic disorder, a neurological disorder or tissue trauma.
• the invention relates to the use of a modified apolipoprotein according to the second or third aspect, or the lipid nanoparticle obtained or obtainable by the method of the fourth or fifth aspect of the invention in delivering a compound to a target, preferably wherein the target is a cell, tissue, and/or organ, even more preferably wherein the target is a lymphoid cell, a myeloid cell, a tumor cell, an endothelial cell, a hematopoietic stem and progenitor cell (HSPC), a hematopoietic stem cell (HSC), a multipotent progenitor (MPP), a common myeloid progenitor cell (CMP), or wherein the targeting body binds a bacterial, viral, fungal or parasitic protein or antigen, preferably wherein the lymphoid or myeloid cell is selected from: a monocyte, a macrophage, an M1-like macrophage, an M2-like macrophage, an
• the invention relates to an in vitro or ex vivo method for introducing a nucleic acid in a cell, the method comprising contacting the lipid nanoparticle as disclosed herein, or the lipid nanoparticle obtained or obtainable by the method as disclosed herein, with a cell.
• the invention in a tenth aspect relates to an in vivo method for introducing a nucleic acid in a cell, the method comprising contacting the lipid nanoparticle as disclosed herein, or the lipid nanoparticle obtained or obtainable by the method as disclosed herein, with a cell.
• the invention in an eleventh aspect relates to a method for the in vivo delivery of a nucleic acid, the method comprising administering the lipid nanoparticle as disclosed herein, or the lipid nanoparticle obtained or obtainable by the method as disclosed herein, to a subject.
• the invention in a twelfth aspect relates to a method for treating a disease or disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of the lipid nanoparticle as disclosed herein, or the lipid nanoparticle obtained or obtainable by the method as disclosed herein, to the subject.
• Fig. 1 depicts an embodiment of the invention, where a modified apolipoprotein (in this case an apolipoprotein-rerouter fusion protein and more particularly an apolipoprotein-nanobody (VHH) fusion protein) is included in a lipid nanoparticle, such as a spherical lipid nanoparticle.
• apolipoprotein nanoparticle such as a spherical lipid nanoparticle.
• the apolipoprotein nanoparticle’s (aNP) main constituents are lipid (e.g. phospholipid), sterol (e.g. cholesterol) and (modified) apolipoprotein.
• Fig. 2 is a schematic overview of apolipoprotein (e.g. apolipoprotein A1 (apoA1))- rerouter fusion protein nanoparticle technology.
• A Targeting or rerouting protein is a molecule capable of binding a molecule (on the cell surface) of a target cell and can include an antibody (fragment), protein ligand, peptide, peptidomimetic, or sugar polymer.
• Apolipoprotein-rerouter fusion protein is a modified apolipoprotein comprising an apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative attached to a targeting body, and more particularly to a rerouting peptide or protein.
• Apoliprotein-rerouter fusion proteins are readily and stably incorporated in lipid nanoparticles, such as spherical lipid nanoparticles, comprising (phospho)lipids, sterols.
• apolipoprotein-rerouter fusion proteins are readily and stably incorporated in spherical lipid nanoparticles comprising (phospho)lipids, sterols, ionizable cationic lipids, and therapeutic payloads including nucleic acids such as small interfering RNA or messenger RNA.
• Fig. 3 shows the expression of VHHCD8-apolipoprotein A1 (apoA1) fusion protein in Clearcoli cells. Minor protein contaminants are present after IMAC purification [lane E1], The most prominent band corresponds to the fusion protein with a molecular weight of 43.3 kDa (rectangle).
• Fig. 4 shows the mean fluorescence intensity (MFI) of fluorescently labelled VHHCD8-apoA1 and apoA1 in mouse splenocytes (upper panel: CD3+ T cells from splenocytes; lower panel: all cells from the spleen).
• Fig. 5 shows the mean fluorescence intensity (MFI) of apolipoprotein nanoparticles (aNPs) formulated with VHHCD8-apoA1 and apoA1 and comprising a fluorescent dye in the lipid structure of the particle in mouse splenocytes.
• MFI mean fluorescence intensity
• Fig. 6 shows the successful formulation of spherical apolipoprotein nanoparticles (aNPs) comprising VHHCD8-apoA1 fusion proteins using cryogenic transmission electron microscopy (cryo-TEM) (bottom panel) and the analysis of nanoparticle size and poly dispersity index (PDI) for 14 days using dynamic light scattering (DLS) (top panel).
• aNPs spherical apolipoprotein nanoparticles
• cryo-TEM cryogenic transmission electron microscopy
• PDI poly dispersity index
• Fig. 7 In vivo biodistribution study setup for of spherical apolipoprotein nanoparticles (aNPs) comprising VHHCD8-apoA1 fusion proteins.
• aNPs spherical apolipoprotein nanoparticles
• Fig. 8 Cell association of VHHCD8-apolipoprotein A1 fusion protein nanoparticles in vivo.
• MFI mean fluorescence intensity.
• Fig. 9 Cell association of VHHCD8-apolipoprotein A1 fusion protein nanoparticles in vivo.
• MFI mean fluorescence intensity.
• Fig. 10 Cell association of VHHCD8-apolipoprotein A1 fusion protein nanoparticles in vivo.
• Fig. 11 FRET assay of lipid nanoparticles containing VHHCD8-apoliprotein A1 fusion proteins and/or IL-2- apolipoprotein A1 fusion proteins.
• Fig. 12 Functional reporter gene expression in mouse splenocytes ex vivo.
• Flow cytometry analysis of mouse splenocytes incubated with apoA1 aNP, VHHCD8-apoA1 aNP, and VHHGFP-apoA1 aNP containing mRNA encoding for fluorescent mCherry protein left panel: CD3+ CD4- mCherry+ T cells, right panel: CD11 b+ mCherry+ myeloid cells).
• the term “and/or” refers to a situation wherein one or more of the stated cases may occur, alone or in combination with at least one of the stated cases, up to with all of the stated cases.
• the term "antigen" refers to a substance to which a binding portion of an antibody may bind.
• the specific immunoreactive sites within the antigen are known as “epitopes” (or antigenic determinants).
• a target for an antibody, or antigen-binding portion thereof, may comprise an antigen, such as is defined herein.
• the term "at least” a particular value means that particular value or more.
• “at least 2" is understood to be the same as “2 or more” i.e., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, ... , etc.
• the term “at most” a particular value means that particular value or less.
• “at most 5" is understood to be the same as "5 or less” i.e., 5, 4, 3, ... .-10, -11 , etc.
• the word “comprise” or variations thereof such as “comprises” or “comprising” will be understood to include a stated element, integer or step, or group of elements, integers or steps, but not to exclude any other element, integer or steps, or groups of elements, integers or steps.
• the verb “comprising” includes the verbs “essentially consisting of” and “consisting of”.
• conventional techniques refers to a situation wherein the methods of carrying out the conventional techniques used in methods of the invention will be evident to the skilled worker.
• the practice of conventional techniques in molecular biology, biochemistry, computational chemistry, cell culture, recombinant DNA, bioinformatics, genomics, sequencing and related fields are well-known to those of skill in the art and are discussed, for example, in the following literature references: Sambrook et al., Molecular Cloning. A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., 1989; Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1987 and periodic updates; and the series Methods in Enzymology, Academic Press, San Diego.
• identity refers to a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" per se has an art-recognized meaning and can be calculated using published techniques. See, e.g.: (Computational Molecular Biology, Lesk, A. M., ED., Oxford University Press, New York, 1988; Biocomputing: Informatics And Genome Projects, Smith, D. W., ED., Academic Press, New York, 1993; Computer Analysis Of Sequence Data, Part I, Griffin, A. M., And Griffin, H.
• nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence encoding a polypeptide of a certain sequence
• the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference amino acid sequence.
• nucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted and/or substituted with another nucleotide, and/or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
• mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence, or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
• a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference amino acid sequence of SEQ ID NO: X is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the amino acid sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: X.
• up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
• These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
• in vitro refers to experimentation or measurements conducted using components of an organism that have been isolated from their natural conditions.
• ex vivo refers to experimentation or measurements done in or on tissue from an organism in an external environment with minimal alteration of natural condition.
• nucleic acid As used herein, the term "nucleic acid”, “nucleic acid molecule” and “polynucleotide” is intended to include DNA molecules and RNA molecules.
• a nucleic acid (molecule) may be single-stranded or double-stranded, but preferably is doublestranded DNA or single- or double stranded RNA, more preferably single- or double stranded RNA.
• nucleic acid typically refers to a polymer (preferably a linear polymer) of any length composed essentially of nucleoside units.
• a nucleoside unit commonly includes a heterocyclic base and a sugar group.
• Heterocyclic bases may include inter alia purine and pyrimidine bases such as adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (II), which are widespread in naturally-occurring nucleic acids, other naturally-occurring bases (e.g., xanthine, inosine, hypoxanthine), as well as chemically or biochemically modified (e.g., methylated), non-natural or derivatised bases.
• A adenine
• G guanine
• C cytosine
• T thymine
• II uracil
• modified nucleobases include, without limitation, 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5- propynylcytosine.
• 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability.
• Sugar groups may include inter alia pentose (pentofuranose) groups such as preferably ribose and/or 2-deoxyribose common in naturally-occurring nucleic acids, or arabinose, 2-deoxyarabinose, threose or hexose sugar groups, as well as modified or substituted sugar groups (such as, without limitation, 2’-0-alkylated, e.g., 2’-0-methylated or 2’-0-ethylated sugars such as ribose; 2’-O-alkyloxyalkylated, e.g., 2’-O-methoxyethylated sugars such as ribose; or 2’-O,4’- C-alkylene-linked, e.g., 2’-O,4’-C-methylene-linked or 2’-O,4’-C-ethylene-linked sugars such as ribose; 2’-fluoro-arabinose, etc.).
• Nucleoside units may be linked to one another by any one of numerous known inter-nucleoside linkages, including inter alia phosphodiester linkages common in naturally-occurring nucleic acids, and further modified phosphate- or phosphonate-based linkages such as phosphorothioate, alkyl phosphorothioate such as methyl phosphorothioate, phosphorodithioate, alkylphosphonate such as methylphosphonate, alkylphosphonothioate, phosphotriester such as alkylphosphotriester, phosphoramidate, phosphoropiperazidate, phosphoromorpholidate, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate; and further siloxane, carbonate, sulfamate, carboalkoxy, acetamidate, carbamate such as 3’-N-carbamate, morpholino, borano, thioether, 3’-
• inter-nucleoside linkages may be phosphate-based linkages including modified phosphate-based linkages, such as more preferably phosphodiester, phosphorothioate or phosphorodithioate linkages or combinations thereof.
• nucleic acid also encompasses any other nucleobase containing polymers such as nucleic acid mimetics, including, without limitation, peptide nucleic acids (PNA), peptide nucleic acids with phosphate groups (PHONA), locked nucleic acids (LNA), morpholino phosphorodiamidate-backbone nucleic acids (PMO), cyclohexene nucleic acids (CeNA), tricyclo-DNA (tcDNA), and nucleic acids having backbone sections with alkyl linkers or amino linkers (see, e.g., Kurreck 2003 (Eur J Biochem 270: 1628-1644)).
• Alkyl as used in this context particularly encompasses lower hydrocarbon moieties, e.g., C1-C4 linear or branched, saturated or unsaturated hydrocarbon, such as methyl, ethyl, ethenyl, propyl, 1- propenyl, 2-propenyl, and isopropyl.
• Nucleic acids as intended herein may include naturally occurring nucleosides, modified nucleosides or mixtures thereof.
• a modified nucleoside may include a modified heterocyclic base, a modified sugar moiety, a modified inter-nucleoside linkage or a combination thereof.
• the term “nucleic acid” further preferably encompasses DNA, RNA and DNA/RNA hybrid molecules, specifically including hnRNA, pre-mRNA, mRNA, cDNA, genomic DNA, amplification products, oligonucleotides, and synthetic (e.g., chemically synthesised) DNA, RNA or DNA/RNA hybrids.
• a nucleic acid can be naturally occurring, e.g., present in or isolated from nature, can be recombinant, i.e. , produced by recombinant DNA technology, and/or can be, partly or entirely, chemically or biochemically synthesised.
• a “nucleic acid” can be double-stranded, partly double stranded, or single-stranded. Where single-stranded, the nucleic acid can be the sense strand or the antisense strand. In addition, nucleic acid can be circular or linear.
• sequence when referring to nucleotides, or “nucleic acid sequence”, “nucleotide sequence” or “polynucleotide sequence” refer to the order of nucleotides of, or within, a nucleic acid and/or polynucleotide.
• a first nucleic acid sequence may be comprised within or overlap with a further nucleic acid sequence.
• Mammalian subjects include humans, domestic animals, farm animals, and zoo-, sports-, or pet-animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, bears, and so on.
• a subject may be alive or dead. Samples can be taken from a subject post-mortem, i.e. after death, and/or samples can be taken from a living subject.
• treatment refers to an approach for obtaining beneficial or desired results including, but not limited to, therapeutic benefit.
• therapeutic benefit is meant eradication or amelioration or reduction (or delay) of progress of the underlying disease being treated.
• a therapeutic benefit is achieved with the eradication or amelioration or reduction (or delay) of progress of one or more of the physiological symptoms associated with the underlying disease such that an improvement or slowing down or reduction of decline is observed in the patient, notwithstanding that the patient can still be afflicted with the underlying disease.
• vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which the nucleic acid molecule capable of transporting has been linked.
• plasmid refers to a circular double stranded DNA loop into which additional DNA segments may be ligated.
• vector may also refer to the viral particle (i.e. viral vector) which contains the nucleic acid of interest.
• a portion of this invention contains material that is subject to copyright protection (such as, but not limited to, diagrams, device photographs, or any other aspects of this submission for which copyright protection is or may be available in any jurisdiction).
• the copyright owner has no objection to the facsimile reproduction by anyone of the patent document or patent invention, as it appears in the Patent Office patent file or records, but otherwise reserves all copyright rights whatsoever.
• Various terms relating to the methods, compositions, uses and other aspects of the present invention are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art to which the invention relates, unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definition as provided herein. The preferred materials and methods are described herein, although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention.
• the present invention is based on the inventors’ finding that apolipoprotein can be modified to target specific cells, tissues, organs or pathogens.
• modified apolipoproteins that bind a targeting body allow targeting of lipid nanoparticles containing such modified apolipoproteins.
• lipid nanoparticles or modified apolipoproteins
• a payload such as a pharmaceutical
• the modified apolipoprotein of the present invention also allows to prepare alipid nanoparticle, wherein the targeting body is exposed to the environment (i.e. aqueous environment) surrounding said apolipoprotein lipid nanoparticle, as a result.
• the invention relates to a modified apolipoprotein comprising an apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative attached to a targeting body, wherein the targeting body is a molecule capable of binding a molecule on the cell surface of a target cell.
• the modified apolipoproteins may be used as such, meaning not as part of a lipid nanoparticle.
• the modified apolipoproteins may serve as a carrier to deliver a payload (e.g. a therapeutic) to a target site.
• a payload could for example be bound to the modified apolipoproteins, for example by a covalent bond.
• the targeting body can be used to target the modified apolipoproteins to a specific site, such as a cell, tissue, organ or pathogen.
• the term attached when referring to the modified apolipoprotein may refer to a stable or semi-stable association, for example but not limited to a covalent bond, a hydrogen bond or van der Waals force, or combinations thereof, such as but not limited to a peptide bond, a sulfur bond, a protein-protein interaction or a protein ligand interaction.
• Targeting body may refer to a stable or semi-stable association, for example but not limited to a covalent bond, a hydrogen bond or van der Waals force, or combinations thereof, such as but not limited to a peptide bond, a sulfur bond, a protein-protein interaction or a protein ligand interaction.
• a targeting body refers to a molecule that allows, when attached to a protein such as an apolipoprotein, the protein to bind to a different target than it would bind when the protein was not fused to the targeting body (or in other words, a different target than that to which it would have innately bound), and/or to bind to its intended target with a higher affinity.
• the targeting body may allow to bind a different target, such as a particular subset of target cells, including binding to a particular subset of a set of cells which would normally be bound by the modified apolipoprotein.
• a different target such as a particular subset of target cells, including binding to a particular subset of a set of cells which would normally be bound by the modified apolipoprotein.
• apoA1 is known to bind receptors on myeloid cells, thus the targeting body may be used to bind a particular subtype of myeloid cells.
• SIRPalpha as a targeting body may allow to target immunosuppressive macrophages.
• Non limiting examples of targeting bodies are an antibody or antigen binding fragment thereof or an antibody fragment, a rerouting peptide or a rerouting protein, preferably wherein the rerouting peptide or rerouting protein is a ligand of a receptor present on the target.
• target refers to the object the modified apolipoprotein or targeting body preferentially binds to.
• a target may refer to a receptor or cell surface molecule such as a protein or proteoglycan, a lipid, a phospholipid, a sugar, a sugar polymer, a cell, a cell type, a tissue or tissue type or an organ.
• apolipoproteins bind to specific ligands.
• the different apolipoproteins found in different lipoproteins e.g. HDL, LDL, VLDL, etc.
• the apolipoproteins are responsible for differences in targeting and binding and thus function of the lipoproteins.
• part of the apolipoprotein has an amphipathic nature and is responsible, together with phospholipids and/or sterols to bind lipids in an aqueous environment, while different parts of the molecule are responsible for interacting with other molecules, e.g. binding to protein receptors.
• apolipoproteins may circulate also as proteins, meaning not as lipoproteins. Therefore, the possibility to modify binding affinity of the apolipoprotein (by adding a targeting body) provides interesting opportunities, as it allows to fine-tune targeting or binding of the apolipoprotein.
• Several applications are envisioned for such modified apolipoproteins:
• the targeting body may simply be used to reroute the apolipoprotein or lipoprotein, for example to make changes in the lipid homeostasis.
• LDL or HDL values in the blood of a subject could be altered by using apolipoprotein combined with a targeting body. This could potentially be exploited for treatment of lipid disorders such as high blood cholesterol levels.
• Second it may be used to reroute a lipoprotein (lipid nanoparticle) with a payload to a predetermined target.
• Lipoproteins or lipid nanoparticles pose interesting methods of carrying a payload such as a pharmaceutical compound. It allows delivery of lipophilic compounds through blood, as the compound may be dissolved in the lipid core of a lipoprotein I lipid nanoparticle.
• An additional advantage is that the lipoprotein consists of naturally occurring compounds and thus is seen as native by the immune system, avoiding triggering an immune response by the pharmaceutical compound.
• apolipoprotein can essentially serve as a carrier for a payload. Advantages are that it greatly reduces clearing of the payload, making it feasible to use payloads that are easily cleared from the blood in a therapeutic setting (e.g. cytokines).
• payload I apolipoprotein combination does not arrive at the intended target for the payload (i.e. the site, cell, tissue or organ where it is intended to exert its effect). This is solved by further including the targeting body.
• the targeting body is selected from an antibody or an antigen binding fragment thereof, a rerouting peptide or a rerouting protein, preferably wherein the rerouting peptide or rerouting protein is a ligand of a receptor present on the target.
• the targeting body may be an antibody or an antigen binding fragment thereof. It is envisioned that any type of antigen binding molecule can in principle be used as a targeting body in the modified apolipoprotein according to the invention.
• the targeting body binds to an antigen which is highly expressed or exclusively present on myeloid cells.
• Suitable targets are known to the skilled person, non-limiting examples are CD11 b, CD11c, CD14 or co-stimulatory molecules such as CD80, CD83, CD86, CD40 or HLA-DR. Therefore in an embodiment the targeting body is a myeloid-targeting peptide or protein selected from an antibody or an antigen binding fragment thereof which binds to CD11b, CD11c, CD14, CD80, CD83, CD86, CD40 or HLA-DR.
• the targeting body may be a protein ligand which binds to a receptor or factor expressed on a myeloid cell, non-limiting examples being CD40L (CD154) and FC domains, but the skilled person is aware of other suitable ligands or cofactors. Therefore, in an embodiment, the targeting body is a myeloid- targeting peptide or a myeloid-targeting protein wherein the myeloid-targeting protein or myeloid-targeting peptide is selected from CD40L (CD154) and FC domains.
• the targeting body is an antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof is selected from a Fragment antigen-binding region (Fab), a Fab2, a single-chain variable fragment (scFv), a scFv- Fc, a dAb-Fc, a free light chain antibody, a half antibody, a bispecific Fab2, a Fab3, a trispecific Fab3 a diabody, a bispecific diabody, a triabody, a trispecific triabody, a minibody, an IgG, an immunoglobulin new antigen receptor (IgNAR), a monovalent IgG, a VhH, a nanobody, or a variable domain of new antigen receptor (VNAR), or an antigen binding fragment thereof, preferably a camelid or shark VhH or derivative thereof or antigen binding fragment thereof.
• Fab Fragment antigen-binding region
• Fab2 fragment antigen binding region
• the antibody or antigen binding fragment may also be a designed antigen binding protein such as but not limited to affibodies, FN3 domains, DARPins or de novo designed protein receptors. It is appreciated that antibodies or antigen binding fragments thereof with a lower molecular weight are preferred due to their reduced size, therefore in a preferred embodiment the antibody or antigen binding fragment thereof is a Fab, scFv, single domain antibody, VhH or VNAR.
• the targeting body may be a rerouting peptide.
• rerouting peptides are receptor binding peptides, and/or ligand mimicking peptides. Therefore, in an embodiment, the rerouting peptide is selected from programmed cell death protein 1 (PD1) or signal-regulatory protein alpha (SIRPa). SIRPalpha as a targeting body may allow to target immunosuppressive macrophages. It is however understood that any peptide with binding specificity to a cell surface receptor could be used as a targeting body.
• PD1 programmed cell death protein 1
• SIRPa signal-regulatory protein alpha
• the targeting body may be a protein such as a receptor ligand, a receptor, or interacting protein.
• the targeting body may be part of a protein for example a protein or ligand binding domain. Therefore, in an embodiment, the rerouting protein is for example selected from CD40L or GP120.
• CD40L can be used to target cells expressing the CD40 receptor.
• GP120 can be used to bind directly to the CD4 T-Cell co-receptor. It is however understood that any protein with binding specificity to a cell surface receptor could be used as a targeting body.
• the targeting body may be a sugar polymer.
• Sugar polymers could be used to direct an apolipoprotein modified with a sugar polymer to specific site or receptor.
• apolipoprotein could be modified with mannose to direct the modified apolipoprotein to the mannose receptor, which is generally expressed in macrophages, dendritic cells, and endothelial cells.
• mannose mannose receptor
• sugar polymer refers to any poly saccharide, thus any molecule comprising at least two saccharides.
• lipoprotein refers to a particle, generally a nanoparticle, of at least one apolipoprotein and lipid molecules, dispersed or dissolved in an aqueous environment.
• the term rerouting refers to targeting the modified apolipoprotein to a different target than it would normally bind to, or reducing the binding to the regular target of the modified apolipoprotein or preventing off-target binding.
• apolipoprotein a1 (apoA1) is known to bind receptors on myeloid cells, thus the targeting body may be used to bind different cells and reduce binding of myeloid cells (for example, the myeloid cell may be a monocyte, a dendritic cell, a tissue macrophage or a granulocyte).
• the targeting body binds a protein on the surface of a lymphoid cell, a myeloid cell, a tumor cell, an endothelial cell, a hematopoietic stem and progenitor cell (HSPC), a hematopoietic stem cell (HSC), a multipotent progenitor (MPP), a common myeloid progenitor cell (CMP), or wherein the targeting body binds a bacterial, viral, fungal or parasitic protein or antigen, preferably wherein the targeting body binds a protein on the surface of a lymphoid cell, a myeloid cell, a tumor cell, or wherein the targeting body binds a bacterial, viral, fungal or parasitic protein or antigen, preferably wherein the lymphoid or myeloid cell is selected from a monocyte, a macrophage, an M1-like macrophage, an M2-like macrophage, an eosinophil, a basophil,
• the myeloid cell may be a blood cell derived from a progenitor cell for granulocytes, monocytes, erythrocytes or platelets.
• the targeting body binds a protein selected from CD1a, CD1b, CD1c, CD1d, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD9, CD10, CD11a, CD11 b, CD11c, CD11d, CDw12, CD13, CD14, CD15, CD15s, CD15u, CD16, CDw17, CD18, CD19, CD20, CD21 , CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31 , CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41 , CD42a, CD42b, CD42c, CD42d, CD43, CD44, CD45, CD45RO, CD45RA, CD45RB, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD51 , CD52, CD53, CD5, CD
• CD14 preferably selected from CD14, CD11b, CD357 (GITR), CD193, CD123, CD117, CD56, CD19, CD38, CD25, CD133, CXCR3, CCR3, CD196, CCR10, CD64, CD206, CLEC4C (CD303), CLEC9A, CD1c, CD163, Alphafetoprotein (AFP), Carcinoembryonic antigen (CEA), CA-125, MUC-1 , Epithelial tumor antigen (ETA), Tyrosinase, and melanoma-associated antigen (MAGE).
• These targets may be used to target specific cell types or subsets of cells.
• the skilled person is aware which marker may be suitable for which cell type(s), for example the following proteins could be used to target specific cells:
• Macrophages CD11 b
• CD357 CD357
• NK cells CD56 B cells: CD19 Plasma cells: CD38 Regulatory T cells: CD25 Subtypes of immune cells: Myeloid progenitor cells: Hematopoietic stem cells: CD133 T helper cell subsets: Th1 : CXCR3, Th2: CCR3, Th17: CD196, Th22: CCR10 Macrophages polarization states (M1-like or M2-like): M1 : CD64, M2: CD206 (mannose-receptor) (e.g. targeted by apolipoprotein bound with nanobody specific for this receptor, or apolipoprotein bound with mannose)
• M1 CD64
• M2 CD206 (mannose-receptor) (e.g. targeted by apolipoprotein bound with nanobody specific for this receptor, or apolipoprotein bound with mannose)
• dendritic cells plasmacytoid dendritic cells: CD303, conventional DC 1 : CLEC9A, conventional DC 2: CD1c
• Tumor-associated macrophages CD163 (or targeted with nanobody against tumor antigen).
• the targeting body is capable of binding to a non- myeloid cell, such as a non-myeloid immune cell, preferably non-myeloid leukocytes, more preferably lymphocytes, more preferably T cells, even more preferably CD8+ T cells.
• a non-myeloid immune cell such as a non-myeloid immune cell, preferably non-myeloid leukocytes, more preferably lymphocytes, more preferably T cells, even more preferably CD8+ T cells.
• the targeting body is capable of binding to cells that are not myeloid cells, but that may differentiate into myeloid cells, such as a hematopoietic stem and progenitor cell (HSPC), like a hematopoietic stem cell (HSC), a multipotent progenitor (MPP), or a common myeloid progenitor cell (CMP).
• HSPC hematopoietic stem and progenitor cell
• HSC hematopoietic stem cell
• MPP multipotent progenitor
• CMP common myeloid progenitor cell
• the targeting body is capable of binding to a non- myeloid cell, such as a non-myeloid immune cell or an endothelial cell.
• Endothelial cells may be targeted by use of a targeting body capable of binding to a surface marker of endothelial cells.
• endothelial cells may be targeted by use of a targeting body capable of binding to Factor VI I l-related antigen such as Factor VIII, a targeting body capable of binding to CD31/PECAM-1 such as CD31 , a targeting body capable of binding to Angiotensin-converting enzyme (ACE/CD143) such as angiotensin, a targeting body capable of binding to CD34 such as L-selectin or a targeting body capable of binding to endoglin (CD105).
• a targeting body capable of binding to Factor VI I l-related antigen such as Factor VIII
• a targeting body capable of binding to CD31/PECAM-1 such as CD31
• ACE/CD143 Angiotensin-converting enzyme
• CD34 such as L-selectin
• CD105 endoglin
• the non-myeloid cell is a lymphocyte, such as a T cell, a B cell or a natural killer (NK) cell.
• the lymphocyte is a T cell, even more preferably a CD8+ T cell.
• the targeting body is an antibody or antigen binding fragment thereof binding to, e.g. specifically binding, to CD8.
• the targeting body may be an antibody or antigen binding fragment thereof binding, preferably specifically binding, to CD8.
• the targeting body may be a VHHCD8 as described in Woodham A.W. et al., Nanobody-antigen conjugates elicit HPV-specific antitumor immune responses, Cancer Immunology Research, 2018, Vol. 6, issue 7, and comprising an amino acid sequence as shown in Supplemental Table 1 of said reference.
• CD8-targeted apolipoprotein nanoparticles as described herein can also be used to generate chimeric antigen receptor (CAR) T cells in vivo.
• CAR chimeric antigen receptor
• the CD8-targeted apolipoprotein nanoparticles can be used to deliver plasmid DNA (pDNA), linear or circular RNA (e.g. linear or circular mRNA), and/or gene editing components encoding instructions to reprogram T cells in vivo.
• pDNA plasmid DNA
• linear or circular RNA e.g. linear or circular mRNA
• gene editing components encoding instructions to reprogram T cells in vivo.
• targeted nucleases can be used to introduce a nucleic acid in a cell.
• the targeted nucleases include, but are not limited to, transcription activator-like effector nuclease (TALEN), zinc finger nuclease (ZNF), clustered regulatory interspaced short palindromic repeats (CRISPR), CRISPR/Cas9, CRISPR/CPFL and combinations thereof, such as for example using single guide RNA or other gene editing components, such as single guide RNA with CRISPR/Cas.
• TALEN transcription activator-like effector nuclease
• ZNF zinc finger nuclease
• CRISPR clustered regulatory interspaced short palindromic repeats
• CRISPR/Cas9 CRISPR/CPFL
• combinations thereof such as for example using single guide RNA or other gene editing components, such as single guide RNA with CRISPR/Cas.
• pDNA or RNA encoding chimeric antigen receptors (CAR) can be delivered into T cells that enables them to recognize and kill tumor cells with a cognate ligand.
• CD8-targeted apolipoprotein nanoparticles as described herein can also be used to modify CD8+ T cell function.
• CD8+ T cell function may be modified through modifying cytokine-cytokine receptor interactions using CD8-targeted apolipoprotein nanoparticles as described to deliver plasmid DNA (pDNA), linear or circular RNA (e.g. linear or circular mRNA), and/or gene editing components as mentioned above encoding instructions for cytokine production in T cells.
• pDNA or mRNA encoding cytokines such as IFN-y, IL-2, IL-10, IL-12, IL-15 may be delivered into T cells to enable them to secrete cytokines.
• cytokines receptors such as IFN-yR, IL-2R, IL-12R, or IL-15R
• CD8+ T cell function may also be modified through regulating immune checkpoints, e.g. CD8+ T cell function may be modified through downregulating immune checkpoints using CD8- targeted apolipoprotein nanoparticles as described to deliver antisense oligonucleotides, small interfering RNA (siRNA), mRNA, and/or gene editing components as mentioned above encoding instructions to downregulate immune checkpoints in T cells.
• siRNA small interfering RNA
• siRNA or gene editing components as mentioned above targeting PD1 , CTLA4, SHP-2, LAG3, or TIM-3 may b delivered to T cells for downregulation of checkpoint molecules that inhibit cytotoxic T cell function in cancer.
• CD8-targeted apolipoprotein nanoparticles as described herein can be used for re-polarization of pathogenic CD8+ T cells in autoimmunity towards a tolerogenic phenotype.
• the CD8-targeted apolipoprotein nanoparticles can be used to deliver antisense oligonucleotides, small interfering RNA (siRNA), mRNA or gene editing components as mentioned above encoding instructions to re-polarize pathogenic T cells.
• mRNA encoding FOXP3 may be delivered into T cells to alter their phenotype into regulatory T cells (T regs).
• CD8+ IL17+ T cells may be re-polarized via delivery of siRNA targeting IL-17 or the RORyt transcription factor.
• the modified apolipoprotein comprises aapoAl with VHH8CD8.
• the VHHCD8-apoA1 modified apolipoprotein comprises or consists of a polypeptide with an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO.
• 7 or 1 or comprises or consists of an amino acid sequence encoded by a nucleic acid with a sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO. 8 or 2.
• the targeting body may be PD1 , CD40L or GP120.
• apolipoproteins are proteins that bind lipids such as triglycerides and cholesterol to form lipoproteins. They transport lipids (and fat-soluble vitamins) in blood, cerebrospinal fluid and lymph. The lipid components of lipoproteins are insoluble in water.
• apolipoproteins and other amphipathic molecules can surround the lipids, creating a lipoprotein particle that is itself water-soluble, and can thus be carried through water-based circulation (i.e., blood, lymph).
• water-based circulation i.e., blood, lymph.
• apolipoproteins interact with lipoprotein receptors and lipid transport proteins, thereby participating in lipoprotein uptake and clearance.
• apolipoproteins function as structural components of lipoprotein particles, ligands for cell-surface receptors and lipid transport proteins, and cofactors for enzymes.
• Different lipoprotein particles contain different classes of apolipoproteins, which influence their function.
• apolipoprotein A1 (apoA1) is the major structural protein component of high-density lipoproteins (HDL), although it is present in other lipoproteins in smaller amounts, and HDL comprises other apolipoproteins.
• the invention is not limited to a particular type of apolipoprotein, therefore in an embodiment, the apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative is selected from apoA1 , apoA-1 Milano, apoA2, apoA4, apoA5, apoB, apoB48, apoB100, apoC-l, apoC-ll, apoC- III, apoC-IV, apoD, apoE, apoF, apoH, apoL, apoL1 , apoL2, apoL3, apoL4, apoL5, apoL6, apoLDI , apoO, apoOL and apoM, or a combination thereof, or a mimetic or derivative thereof, preferably selected from apoA1 , apoA2, apoA4, apoA5, apoB100, apoC-l, apoC- II, apoC-lll
• the apolipoprotein component of the modified apolipoprotein is apoA1 or an apoA1 mutant.
• the apolipoprotein component may also be an apolipoprotein fragment.
• the apolipoprotein fragment retains the biological activity of the full-length apolipoprotein, such as the ability of the apolipoprotein to integrate into a lipid nanoparticle or to target to the myeloid compartment.
• the apolipoprotein fragment comprises at least the ATP Binding Cassette Subfamily A Member 1 (ABCA1), ATP Binding Cassette Subfamily G Member 1 (ABCG1) and/or Scavenger receptor class B type 1 (SR-BI) binding regions of the full- length apolipoprotein, thereby allowing binding to a myeloid cell.
• the apolipoprotein fragment comprises at least the alpha helices of the full-length apolipoprotein. These helices are hydrophilic on one side (interact with aqueous environment) and hydrophobic (interacts with lipids in the particle) on the other side.
• the fragment may be a N- and/or C-terminally truncated form of the full-length peptide, polypeptide or protein from which it is derived.
• the fragment may comprise at least about 30%, e.g., at least about 50% or at least about 70%, preferably at least about 80%, e.g., at least about 85%, more preferably at least about 90%, and yet more preferably at least about 95% or even about 99% of the amino acid sequence length of said full-length peptide, polypeptide, or protein from which it is derived.
• the fragment may include a sequence of > 5 consecutive amino acids, or > 10 consecutive amino acids, or > 20 consecutive amino acids, or > 30 consecutive amino acids, e.g., > 40 consecutive amino acids, such as for example > 50 consecutive amino acids, e.g., > 60, > 70, > 80, > 90, > 100, or > 200, consecutive amino acids of the corresponding full-length peptide, polypeptide, or protein.
• the apolipoprotein component such as an apolipoprotein fragment, comprises the myeloid-binding portion of full-length apolipoprotein.
• the apolipoprotein component is an apolipoprotein mutant comprising a mutation that allows chemical conjugation of the apolipoprotein to a targeting body, wherein the targeting body is a molecule capable of binding a molecule on the cell surface of a target cell.
• the apolipoprotein component may also be an apolipoprotein mutant comprising a serine to cysteine substitution, such as the mutant as defined by SEQ ID NO: 9, 10, 11 or 12 as described elsewhere herein.
• Peptide sequences for the different proteins described herein, or nucleic acid sequences for the genes encoding the different proteins described herein, are readily available to the skilled person, for example from the LICSC Genome Browser (http://genome.ucsc.edu/), Ensembl genome browser (https://www.ensembl.org) and NCBI (https://www.ncbi.nlm.nih.gov/protein). Consensus sequences for different proteins or genes are readily derived from these sources, although it is understood a certain variation may be present due to, but not limited to, genetic variation and multiple splice variants of the gene.
• this should be interpreted to encompass sequence variations due to genetic variation and splice variants. Therefore, when used herein when referring to a certain protein, this should be interpreted as the corresponding consensus protein sequence as retrieved from the Ensembl genome browser, or the consensus nucleic acid (gene) sequence as retrieved from the Ensembl genome browser, or a protein sequence 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the corresponding consensus protein sequence as retrieved from the Ensembl genome browser, or a gene sequence 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the corresponding consensus gene sequence as retrieved from the Ensembl genome browser, or a nucleic acid sequence encoding a protein 80%, 85%, 90%, 91 %, 92%, 93%, 94%
• apolipoprotein mimetics are synthetic peptides or proteins that mimic the function or structure of apolipoproteins.
• Several apolipoprotein mimetics are known and for example Wolska et al. (Cells. 2021 Mar; 10(3): 597., incorporated by reference in its entirety) review different apoA1 , apoE and apoC-ll mimetics described in the literature.
• aapoAl mimetic peptides have largely been designed based on their ability to efflux cholesterol from cells.
• apoA1 mimetic peptides are simply just amphipathic helices and, in fact, many have no primary amino acid homology to apoA1.
• exemplary aapoAl mimetics are aapoAl mimetic 18A, aapoAl mimetic 2F and aapoAl mimetic 37pA.
• apoE has several putative atheroprotective functions, many different types of apoE-based peptides have been reported.
• One of the main goals in the design of these peptides is to facilitate the hepatic clearance of apoB-containing lipoproteins.
• these peptides usually have not only the receptor-binding motif from the N-terminal domain of apoE, but also a lipid-binding region based on the C-terminal domain of apoE or some other sequence.
• apoC-ll mimetics have been described either based on a shortened first helix (18A) linked to the LPL-activation domain of apoC-ll, or mimetics where both the first and second helix are based on the native apoC-ll helices with amino acid substitutions to enhance bihelical binding to lipoproteins.
• an apolipoprotein mimetic refers to a synthetic protein or peptide which shares a structural and/or functional feature with the respective apolipoprotein.
• the shared structural feature may be a primary, secondary or tertiary peptide structure such as the peptide sequence, presence of structures such as an alpha helix or beta sheet or three-dimensional structure of the peptide, or the functional feature may be a similarity in binding to a certain target such as a receptor.
• the apolipoprotein is capable of binding lipids, more preferably forming lipid particles, in a similar manner as the corresponding apolipoprotein.
• the apolipoprotein mimetic may be able to bind to a myeloid cell to the same or a similar extent as the respective apolipoprotein.
• the apolipoprotein mimetic of apoA1 is preferably able to bind to a myeloid cell to the same or a similar extent as apoA1 .
• the modified apolipoprotein is a combination of apoA1 with a targeting body. In an embodiment the modified apolipoprotein is a combination apoA1 mimetic with a targeting body. In an embodiment the modified apolipoprotein is a combination apoE with a targeting body.
• the modified apolipoprotein is a combination of an apolipoprotein component (e.g. an apoA1 mutant, preferably a human apoA1 mutant), with a targeting body.
• an apolipoprotein component e.g. an apoA1 mutant, preferably a human apoA1 mutant
• the modified apolipoprotein is a combination of an apoA1 mimetic with a targeting body.
• the modified apolipoprotein is a combination apoE with a targeting body.
• the human apoA1 protein sequence is annotated under NCBI Genbank (http://www.ncbi.nlm.nih.gov/) accession number NP_001304947.1 (isoform 1 preproprotein), and Uniprot (www.uniprot.org) accession number P02647.1.
• the apolipoprotein component is apoA1 (e.g. as derived from the human precursor of apoA1 as defined by SEQ ID NO. 9, of which the first 18 amino acids form the signal peptide) or an apolipoprotein component derived from apoA1 (e.g. as defined by SEQ ID NO. 10, 11 or 12).
• the apolipoprotein component is human apoA1 as defined by SEQ ID NO. 13.
• a reactive handle may be used. Therefore, apolipoprotein components derived from apoA1 comprising a cysteine in the place of a serine at position 147 (e.g. as defined by SEQ ID NO. 11) or 279 (e.g. as defined by SEQ ID NO: 12) could be useful to prepare a modified apolipoprotein.
• the apolipoprotein component comprises, consists essentially of or consists of an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO. 9, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 10, SEQ ID NO. 11 or SEQ ID NO.
• sequence as defined by SEQ ID NO. 14, SEQ ID NO. 10, SEQ ID NO. 11 or SEQ ID NO. 12 comprise N-terminally the amino acid sequence GLVPRGSIDD (SEQ ID NO.
• SEQ ID NO. 15 comprises N-terminally a 6His tag followed by the amino acid sequence GLVPRGSIDD (SEQ ID NO. 16).
• the thrombin cleavage site as could be used to remove the N-terminal His tag from the peptide.
• the apolipoprotein component comprises, consists essentially of or consists of, an amino acid sequence at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO. 10, wherein SEQ ID NO. 10 comprises a cysteine at position 7 of SEQ ID NO. 10.
• the apolipoprotein component comprises, consists essentially of or consists of, an amino acid sequence at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO. 11 , wherein SEQ ID NO. 10 comprises a cysteine at position 150 of SEQ ID NO. 11 .
• the apolipoprotein component comprises, consists essentially of or consists of, an amino acid sequence at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO. 12, wherein SEQ ID NO. 10 comprises a cysteine at position 239 of SEQ ID NO. 12.
• fusion protein when referring to a modified apolipoprotein the term fusion protein should be interpreted as an apolipoprotein and covalently attached thereto a targeting body.
• the covalent attachment may be due to the in frame coding of a peptide or protein sequence by the nucleotide sequence that encodes the fusion protein.
• the covalent attachment may be due to covalent linkage of the targeting body to the apolipoprotein, for example via a sulfur bond such as a thioether bond, formed at a cysteine residue of the apolipoprotein.
• the payload may if it is a peptide or protein, optionally be a fusion protein with the modified apolipoprotein.
• the targeting body and/or the payload and/or the apolipoprotein may include the site-specific incorporation of non-natural amino acids such as para-azidophenylalanine, which can be used in subsequent (strain- promoted) “click” (conjugation) reactions with alkyne modified reagents.
• non-natural amino acids such as para-azidophenylalanine
• the modified apolipoprotein may comprise a linker, such as a flexible linker, between the apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative and the targeting body.
• the linker may be a glycine- serine linker, such as a (GGS)n-linker, wherein n is 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably a (GGS)4 (SEQ ID. 23)-linker.
• the modified apolipoprotein may comprise one or more tags, such as at the N- and/or C-terminal end of the modified apolipoprotein.
• the one or more tags such as a 6His-tag or strep-tag may allow purification of the modified apolipoprotein.
• the targeting body may be covalently attached to any portion of the apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative.
• a linker such as a flexible linker, may be used to allow such covalent attachment.
• the targeting body is located N- or C-terminally of said apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative in said modified apolipoprotein.
• an immune response refers to a reaction which occurs within an organism by the immune system.
• the immune response may be the innate immune response or the adaptive immune response or the complement immune system.
• Immune responses when referred herein include but are not limited to: secretion of a pro- inflammatory molecule; secretion of an anti-inflammatory molecule; phagocytosis; antibody production, presentation or secretion; antigen presentation; activation, proliferation, suppression or differentiation of an immune cell; binding of an immune cell to a target, or initiation of an immune related cellular signaling cascade.
• the modified apolipoprotein further comprises a payload.
• the payload may be bound to the modified apolipoprotein, for example by a covalent bond.
• a payload refers to a molecule which is to be delivered a target site. Non limiting examples are a nucleic acid or a nucleic acid analog, a therapeutic, a biologic, a cytokine, a chemokine, a hormone, a growth factor, or combinations thereof, although the skilled person may be aware of additional types of payloads.
• the payload may be an immunomodulatory molecule and interfere with, change, stimulate or suppress the innate immune response or the adaptive immune response or the complement immune system.
• the payload may be a protein, peptide or organic compound.
• the payload may be isolated or derived from a natural source, cloned or synthesized. Therefore, in an embodiment the payload is selected from a nucleic acid or a nucleic acid analog, a therapeutic, a biologic, a cytokine, a chemokine, a hormone, a growth factor, or combinations thereof.
• the payload may be a cytokine.
• Cytokines are known to the skilled person to be small proteins of approximately 5 to 20 kDa and are important in cell signaling.
• a cytokine may refer to: a four-alpha-helix bundle family cytokine, such as the IL-2 subfamily, the interferon (IFN) subfamily or the IL-10 subfamily; the IL-1 family; the cysteine knot cytokines such as the TGFbeta family; the IL-17 family.
• the cytokine is preferably selected from IL18, IL18BP, IL1A, IL1 B, IL1 F10, IL1 F3/IL1 RA, IL1 F5, IL1 F6, IL1 F7, IL1 F8, IL1 RL2, IL1 F9, IL33, BAFF, 4- 1 BBL, TNFSF8, CD40LG, CD70, CD95L/CD178, EDA-A1 , TNFSF14, LTA/TNFB, LTB, TNFalpha, TNFSF10, TNFSF11 , TNFSF12, TNFSF13, TNFSF15, TNFSF4, IFNA1 , IFNA10, IFNA13, IFNA14, IFNA2, IFNA4, IFNA7, IFNB1 , IFNE, IFNG, IFNZ, IFNA8, IFNA5/IFNaG, IFNw/IFNW1 , CLCF1 , CNTF, IL11 ,
• the cytokine is selected from the IL-2 subfamily, the interferon subfamily, the IL-10 subfamily, the IL-1 family, the TGFbeta family, or the IL-17 family, or combinations thereof, more preferably wherein the cytokine is selected from I L-1 p , IL-2, IL-4, IL-38, or combinations thereof.
• the modified apolipoprotein is a fusion protein of a modified apolipoprotein with IL-1 B.
• IL-1 B is also known as IL1 B, IL-1 IL1 F2 or interleukin 1 beta, and is a cytokine protein that in humans is encoded by the IL1B gene.
• the modified apolipoprotein is a fusion protein of a modified apolipoprotein with IL-2.
• IL-2 is also known as IL2 TCGF, lymphokine or interleukin 2, and is an interleukin that regulates the activities of leukocytes that are responsible for immunity.
• the modified apolipoprotein is a fusion protein of a modified apolipoprotein with IL-4.
• IL-4 is also known as BSF-1 , IL4 or interleukin 4
• the modified apolipoprotein is a fusion protein of a modified apolipoprotein with IL-38.
• IL-38 is also known as IL38, IL1 F10 interleukin 38, interleukin 1 family member 10 or IL1 -theta, and is a protein that in humans is encoded by the IL1 F10 gene.
• the payload may be a chemokine.
• the chemokine is preferably selected from CCL1/TCA3, CCL11 , COL 12/M CP-5, CCL13/MCP-4, CCL14, CCL15, CCL16, CCL17/TARC, CCL18, CCL19, CCL2/MCP-1 , CCL20, CCL21 , CCL22/MDC, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL3L3, CCL4, CCL4L1/LAG- 1 , CCL5, CCL6, CCL7, CCL8, CCL9, CX3CL1 , CXCL1 , CXCL10, CXCL11 , CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17, CXCL2/MIP-2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7/Ppbp,
• the payload is a hormone.
• Hormones are known to the skilled person to be signaling molecules in multicellular organisms, that are transported to distant organs to regulate physiology and behavior.
• the hormone is selected from Adrenaline (also known as epinephrine), Melatonin, Noradrenaline (also known as norepinephrine), Triiodothyronine, Thyroxine, Dopamine, Prostaglandins, Leukotrienes, Prostacyclin, Thromboxane, Amylin (also known as Islet Amyloid Polypeptide), Anti-Mullerian hormone (also known as Mullerian-inhibiting factor/hormone), Adiponectin, Adrenocorticotropic hormone (also known as corticotropin), Angiotensinogen, Angiotensin, Antidiuretic hormone (also known as vasopressin, arginine vasopressin), Atrial natriuretic peptide (also known as a
• the payload is a growth factor.
• Growth factors are known to the skilled person as naturally occurring substances capable of stimulating cell proliferation, wound healing, and occasionally cellular differentiation.
• the growth factor is selected from Adrenomedullin (AM), Angiopoietin (Ang), Autocrine motility factor, Bone morphogenetic proteins (BMPs), Ciliary neurotrophic factor (CNTF), Leukemia inhibitory factor (LIF), lnterleukin-6 (IL-6), Macrophage colony- stimulating factor (M-CSF), Granulocyte colony-stimulating factor (G-CSF), Granulocyte macrophage colony-stimulating factor (GM-CSF), Epidermal growth factor (EGF), Ephrin A1 , Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin B1 , Ephrin B2, Ephrin B3, Erythropoietin (EPO), Fibroblast growth factor (FGF), Fibroblast
• the growth factor is selected from VEGF, EGF, CNTF, LIF, Ephrins, FGF, GDNF, HDF, HDGF, IGF, KGF, MSF, NRG, BDNF, NGF, Neurotrophin, PGF, PDGF, RNLS, TCGF, TGF, TNF, WNT or combinations thereof.
• the payload is a hematopoietic growth factor.
• the hematopoietic growth factor is selected from IL-3, CSF-1 (M-CSF), GM-CSF, G-CSF, a member of the IL-12 family of interleukins or erythropoietin or combinations thereof.
• M-CSF CSF-1
• GM-CSF GM-CSF
• G-CSF a member of the IL-12 family of interleukins or erythropoietin or combinations thereof.
• modified apolipoproteins as described herein may be used as proteins or as lipid nanoparticles.
• apolipoprotein may circulate as such (meaning not incorporated in a lipoprotein or lipid nanoparticle).
• This application may be suitable to deliver payload, for example a cytokine, to a target site.
• payload for example a cytokine
• apolipoproteins can circulate as proteins but may also form lipoproteins in situ. It may however also be advantageous to include the modified apolipoprotein in a lipid nanoparticle. Therefore, in an aspect the invention relates to a lipid nanoparticle comprising one or more modified apolipoproteins as described as herein.
• apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative may function as a scaffold to help the formation of the nanoparticle together with the phospholipids, and sterols.
• the apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative forms part of the lipid nanoparticle structure.
• at least a part of said modified apolipoprotein is exposed to the environment (i.e. aqueous environment) surrounding said lipid nanoparticle.
• part of the apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative is exposed to the environment surrounding said lipid nanoparticle (e.g. see Fig. 2).
• fusion of a targeting body to the apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative typically allows said targeting body to be wholly exposed to the environment surrounding said apolipoprotein lipid nanoparticle (e.g. see Fig. 2).
• the targeting body is not embedded within the lipid nanoparticle.
• said targeting body may move freely and exert its natural function(s), such as its cell targeting function.
• the lipid nanoparticle is not a phospholipid bilayer.
• the phospholipid is selected from a phosphatidylcholine (PC), a phosphatidylethanolamine (PE), a phosphatidylserine and a phosphatidylglycerol or combinations thereof.
• PC phosphatidylcholine
• PE phosphatidylethanolamine
• PEG phosphatidylserine
• phosphatidylglycerol phosphatidylglycerol
• the phospholipid is selected from the group consisting of 1 ,2-diphytanoyl-sn-glycero-3- phosphocholine (PHPC), dilauroylphosphatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dilauroylphosphatidylglycerol (DLPG), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), dioleoylphosphatidylglycerol (DOPG), dilauroyl phosphatidylethanolamine (DLPE), dimyristoyl phosphatidylethanolamine (DLPE), dim
• the sterol is selected from cholesterol, desmosterol, stigmasterol, p-sitosterol, ergosterol, hopanoids, hydroxysteroid, phytosterol, steroids, hydrogenated cholesterol, campesterol, zoosterol, or combinations thereof.
• the modified apolipoprotein may further be bound to a payload.
• the apolipoprotein may also be an apolipoprotein mimetic or derivative.
• apolipoprotein mimetic or derivative typically two types of nanoparticles can be distinguished: disc-like nanoparticles and spherical nanoparticles. Both comprise an outer layer of phospholipid, sterol and the modified apolipoprotein as described herein. The two differ in that the spherical nanoparticles further comprise a substantially hydrophobic core, while the disc-like nanoparticle lack a core and consequently form a disc-like shape.
• the core may typically comprise lipids, but not necessarily so.
• the lipid nanoparticle is a sphere.
• Spherical nanoparticles enable linking of (many) more fusion proteins depending on the size than, for example, disc-like shape nanoparticles. Furthermore, spherical nanoparticles facilitate the encapsulation of larger payloads, such as mRNA or gene editing components, or a larger amount of payload (e.g. in case of small molecule drugs or small lipophilic payloads), compared to disc-like nanoparticles.
• the lipid nanoparticle comprises a payload
• the lipid nanoparticle comprises a core surrounded by a surface layer
• the core comprises the payload and the surface layer comprises the apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative, the phospholipids, the targeting body, and the sterols.
• the invention relates to a lipid nanoparticle comprising an outer layer and optionally a core, wherein the outer layer comprises:
• the core if present, comprises at least one core component selected from: a lipid, a cationic lipid, or a polyvalent molecule.
• the outer layer is essentially a phospholipid monolayer comprising additional components, at least cholesterol and modified apolipoprotein.
• a lipid nanoparticle refers to an assembly of phospholipids and sterol and one or more apolipoproteins that is soluble in an aqueous solution.
• the particles may comprise lipids, in which case the lipids are encapsulated by the phospholipids and sterols.
• the nanoparticles may comprise further components such as additional proteins or a payload. Therefore, in an embodiment the lipid nanoparticle as defined herein further comprises lipids.
• the lipid nanoparticle comprises a native (e.g. unfused) apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative, in addition to the apolipoprotein, apolipoprotein derivative, apolipoprotein mimetic or apolipoprotein mimetic derivative which forms part of the modified apolipoprotein as described herein.
• the lipid nanoparticle as defined herein further comprises a payload as defined herein above.
• the payload may for example be a pharmaceutical compound.
• the lipid nanoparticle core is particularly suitable for lipophilic payloads but may also be used for amphipathic molecules.
• the pharmaceutical compound may be an organic compound, peptide, protein, nucleic acid or nucleic acid analog, biologic or lipid. Therefore, in an embodiment the lipid nanoparticle further comprises a payload, preferably wherein the payload is selected form a nucleic acid or a nucleic acid analog, a therapeutic, a biologic or combinations thereof. Alternatively the payload may be bound to the outer layer of the lipid nanoparticle, e.g. to the (modified) apolipoprotein, or the payload may be comprised in the phospholipid layer.
• the payload may be a nucleic acid or a nucleic acid analog.
• examples may be but are not limited to mRNA, siRNA, sgRNA, miRNA, piRNA, snRNA, snoRNA, srRNA or tsRNA.
• the nucleic acid analogue may be peptide nucleic acid (PNA), Morpholino and locked nucleic acid (LNA), as well as glycol nucleic acid (GNA), threose nucleic acid (TNA) and hexitol nucleic acids (HNA), or mixtures or combinations thereof.
• PNA peptide nucleic acid
• LNA Morpholino and locked nucleic acid
• GNA glycol nucleic acid
• TAA threose nucleic acid
• HNA hexitol nucleic acids
• the lipid nanoparticle comprises a nucleic acid and a cationic or ionizable cationic lipid.
• the nucleic acid and the cationic or ionizable cationic lipid are comprised by the core, and the modified apolipoprotein and the phospholipid are comprised by the outer layer.
• the present invention thus also encompasses a lipid nanoparticle comprising an outer layer and a core, wherein the outer layer comprises: - a phospholipid;
• the core comprises a nucleic acid and a cationic or ionizable cationic lipid.
• Nucleic acid containing apolipoprotein particles of this kind are described in WO/2022/268913, the entire contents of which are incorporate by reference herein.
• the nanoparticles are engineered to complex nucleic acids, which are hydrophilic in nature, using helper molecules to draw the nucleic acids into the hydrophobic nanoparticle core.
• helper molecules to draw the nucleic acids into the hydrophobic nanoparticle core.
• cationic hydrophobic molecules are employed.
• the cationic group can complex with the anionic phosphate groups in the sugar phosphate backbone via ionic interactions.
• the hydrophobic part of the helper molecule forms a shell around the hydrophilic nucleic acid molecule.
• the cationic helper molecules can be either permanently charged or ionizable.
• the content of cationic material in nanoparticle formulations may range from a cationic-to-anionic ratio of 1 :1 to 25:1. This ratio, often referred to as the N/P (nitrogen/phosphate) ratio, is based on the number of positive charges in the (ionizable) cationic lipid (often nitrogen-based) versus the number of negative charges in the nucleic acid payload (usually phosphate).
• the N/P ratio is the ratio between the cumulative molar amount of cationic and/or ionizable groups in the cationic or ionizable lipid component(s) (N) and the cumulative molar amount of phosphate groups in the nucleic acid component(s) (P).
• the N/P ratio of the nanoparticles as taught herein is from 1 to 25, from 1 to 20, from 1 to 15, from 1 to 12, from 1 to 9, from 1 to 6, or from 1 to 3.
• the N/P ratio of the nanoparticles as taught herein may be 3, 6, 9 or 12.
• the nucleic acidcontaining nanoparticles described herein have an outer layer comprising mainly the modified apolipoprotein, phospholipid and optional sterol, and a core comprising cationic or ionizable cationic lipid and the nucleic acid.
• the core of the nanoparticle comprises an assembly of nucleic acid interacting with the (ionizable) cationic lipid, wherein this core of the nanoparticle is surrounded by a lipid shell comprising, consisting essentially of or consisting of the modified apolipoprotein, phospholipid and optional sterol.
• the nucleic acid is located within (i.e.
• the payload (i.e. nucleic acid) of the nanoparticles of this invention is not bound by ionic interactions at the outside (surface) of the particle. Binding of nucleic acid to the outside surface of the particle is undesired as the nucleic is left exposed to the immediate surroundings, presumably making the particles more toxic as well as leading to fast (bio)-degradation of the nucleic acid payload.
• the modified apolipoprotein is located at the outer surface of the nanoparticle and/or is exposed to the surroundings of the nanoparticle.
• the core of the nanoparticle may be solid and not have or bear a significant aqueous void or reservoir in the core.
• the core of the nanoparticle is non-aqueous.
• the core of the nanoparticle is not surrounded by a lipid bi-layer, such as present in vesicle-like or liposomal particles with lipid bi-layers surrounding an aqueous core.
• the nanoparticles do not comprise synthetic (nonnatural) hydrophilic polymers or (lipid) conjugates of such polymers, such as most notably polyethylene-glycol (PEG).
• synthetic (nonnatural) hydrophilic polymers or (lipid) conjugates of such polymers such as most notably polyethylene-glycol (PEG).
• PEG polyethylene-glycol
• the nanoparticle core further comprises a filler, preferably a filler selected from a triacylglyceride and a cholesterol acyl ester, or combinations thereof, such as wherein the triacylglyceride is tricaprylin and/or wherein the cholesterol acyl ester is cholesteryl caprylate and/or cholesteryl oleate. Cholesteryl acetate may also be employed as filler material. Yet other filler materials that can be applied are di-glycerides or tri-glycerides or other esters derived from C1-C18 carboxylic acids, preferably C6-C18 fatty acids, where these carboxylic acids and fatty acids may be saturated or unsaturated.
• a filler preferably a filler selected from a triacylglyceride and a cholesterol acyl ester, or combinations thereof, such as wherein the triacylglyceride is tricaprylin and/or wherein the cholesterol acyl ester is cholesteryl caprylate and/or
• the filler is a tri-glyceride derived from C6-C18 fatty acids are preferred.
• additional hydrophobic filler molecules can be included in the core of nanoparticle formulations. Their main application is to alter nanoparticle physicochemical properties and/or improve stability.
• the nucleic acid is RNA, DNA or a nucleic acid analogue.
• the RNA is microRNA (miRNA), small interfering RNA (siRNA), piwi-interacting RNA (piRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), transfer RNA (tRNA), tRNA-derived small RNA (tsRNA), small regulatory RNA (srRNA), messenger RNA (mRNA), modified mRNA, ribosomal RNA (rRNA), long non-coding RNA (IncRNA), or guide RNA (gRNA), or combinations thereof and/or modifications thereof.
• the DNA is single stranded or double stranded DNA.
• the nucleic acid is an antisense oligonucleotide and the antisense oligonucleotide is single strand DNA or RNA consisting of nucleotide or nucleoside analogues containing modifications of the phosphodiester backbone or the 2’ ribose.
• the nucleotide or nucleoside analogues are selected from locked nucleic acid (LNA), bridged nucleic acid (BNA), morpholino or peptide nucleic acid (PNA), glycol nucleic acid (GNA), threose nucleic acid (TNA), hexitol nucleic acids (HNA), or mixtures or combinations thereof.
• LNA locked nucleic acid
• BNA bridged nucleic acid
• PNA morpholino or peptide nucleic acid
• GNA glycol nucleic acid
• TPA threose nucleic acid
• HNA hexitol nucleic acids
• nucleic acid is conjugated, and the nucleic acid conjugate is incorporated into the nanoparticle of the invention.
• Nucleic acid conjugates include lipid conjugates with for example phospholipids or with sterols such as cholesterol or with hydrophobic alkyl chains.
• Nucleic acid conjugates also include conjugates with oligomers or polymers. Preferably, these oligomers or polymers are of a hydrophobic nature.
• the nucleic acid is incorporated as such or 'as is' within the nanoparticle, meaning that the nucleic acid is not being conjugated.
• ionizable cationic lipid refers to a lipid which has a neutral charge at physiological pH (e.g. at pH 7 to 7.5, preferably at pH 7.3 to 7.5, such as at -pH 7.4) and which is protonated or positively charged at a lower pH (e.g. at pH 1 to 5, preferably at pH 1 to 4, such as at pH 4). It is understood that ionizable cationic lipids are particularly useful, as they may be protonated at low pH thus facilitating binding to the hydrophilic nucleic acid. By subsequently raising the pH the lipids may become (partly) neutral further facilitating inclusion in a hydrophobic environment, e.g. the hydrophobic core of a nanoparticle.
• the ionizable lipids may remain positively charged within the nanoparticles, even though the pH of the surrounding aqueous solution has been raised to physiological pH, such as about 7.4, due to the action of the surface layer of the nanoparticle that comprises phospholipid, optionally sterol, and modified apolipoprotein, and/or due to the nonaqueous environment within the nanoparticle.
• ionizable cationic lipids are theorized to facilitate the endosomal escape of the nucleic acid in the target cells, where due to the low pH the ionizable cationic lipid will be protonated.
• Non-limiting examples of ionizable cationic lipids are DLin-DMA (2-[2,2- bis(octadeca-9,12-dienyl)-1 ,3-dioxolan-4-yl]-N,N-dimethylethanamine), DLin-KC2-DMA (2-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]-1 ,3-dioxolan-4-yl]-N,N-dimethylethanamine) and DLin-MC3-DMA ([(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate) as represented by formula 1 below:
• ionizable cationic lipids can be employed for preparing the nanoparticles of this invention, as various series of ionizable cationic lipids have been developed and reported on in literature.
• Further non-limiting examples include molecules CKK-E12, C12-200, L319, Acuitas-A9, Moderna-L5, TT3 and ssPalmE (such as described in, for example, Witzigmann et al., Advanced Drug Delivery Reviews 159 (2020) 344-363; doi.org/10.1016/j.addr.2020.06.026).
• the ionizable lipid may further be an ionizable triglyceride.
• a non-limiting example is the compound represented by formula 2:
• the ionizable lipid may further be a cholesterol ester (also named a cholesteryl ester).
• a cholesterol ester also named a cholesteryl ester.
• a non-limiting example is represented by formula 3:
• cationic lipid refers to a positively charged lipid at physiological pH (e.g. pH 7.4).
• cationic lipids are DOTMA (1 ,2- di-O-octadecenyl-3-trimethylammonium propane), DOGS (2,5-bis(3- aminopropylamino)-N-[2-[di(heptadecyl)amino]-2-oxoethyl]pentanamide), DOSPA (2- [3-[4-(3-aminopropylamino)butylamino]propylcarbamoylamino]ethyl-[2,3-bis[[(Z)- octadec-9-enoyl]oxy]propyl]-dimethylazanium) and DOTAP (1 ,2-dioleoyl-3- trimethylammonium-propane).
• ionizable cationic lipid molecules wherein the tertiary amine moiety has been converted to a quaternary ammonium moiety, for example by alkylation, such as by methylation (-Me), ethylation (-Et), benzylation (-Bn) or ethoxylation (-CH2CH2-OH).
• alkylation such as by methylation (-Me), ethylation (-Et), benzylation (-Bn) or ethoxylation (-CH2CH2-OH).
• the resultant quaternary ammonium molecule has a permanent positive (cationic) charge, and accordingly also bears a counter anion, for example a chloride anion.
• only ionizable cationic lipids are used to prepare the nucleic acid-containing nanoparticles as taught herein. Accordingly, in an embodiment, the nanoparticles as taught herein do not comprise cationic lipids.
• only cationic lipids are used to prepare the nucleic acidcontaining nanoparticles as taught herein. Accordingly, in an embodiment, the nanoparticles as taught herein do not comprise ionizable cationic lipids.
• a combination of ionizable cationic lipids and cationic lipids are used to prepare the nucleic acid-containing nanoparticles as taught herein.
• the term “payload” in particular refers to the nucleic acid, preferably in combination with the cationic and/or ionizable cationic lipids.
• lipid is well known in the art, and as used herein may in particular be considered to encompass both lipids, i.e. naturally occurring hydrophobic biomolecules such as for example fatty acids, mono-, di- or tri-glycerides of fatty acids, sterol (derivatives) or phospholipids, and lipid-like biomolecules. It is noted that the cationic lipids or ionizable cationic lipids (or lipidoids) described herein are typically not lipids within the most narrow interpretation of the term, i.e.
• hydrophobic biomolecules such as for example fatty acids, mono-, di- or tri-glycerides of fatty acids, sterol (derivatives) or phospholipids, but are lipid-like biomolecules that resemble lipid biomolecules, i.e. they preferably contain groups that are biocompatible (such as e.g. esters or amides), and/or are constructed using naturally occurring building blocks (e.g. fatty acids, glycerol, cholesterol).
• biocompatible such as e.g. esters or amides
• the cationic or ionizable cationic lipid is selected from an ionizable cationic ester of a long chain alcohol, an ionizable cationic ester of a diglyceride or an ionizable cationic ester of a sterol or combinations thereof.
• the ionizable cationic ester of a long chain alcohol may for example be an ester of a tertiary amine with a carboxy group such as a compound with the formula (CH 3 ) 2 N(CH 2 )nCOOH, wherein n is an integer of 1 or more, for instance n is 1 to 12; for example 3-dimethylamino-propionic acid or 4-dimethylamino-butyric acid or 5 dimethylamino-pentanoic acid.
• the ester is formed with a long chain alcohol.
• the long chain alcohol is preferably a primary or secondary alcohol with a straight or branched chain length of 8 or more carbon atoms, for example 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20 or more.
• the ionizable cationic ester of a diglyceride is preferably a diacyl glycerol (i.e. a di-glyceride) coupled at the 1 or 2 position with a tertiary amine with a carboxy group such as a compound with the formula (CH3)2N(CH2) n COOH, wherein n is an integer of 1 or more, for instance n is 1 to 12; for example 3-dimethylamino-propionic acid or 4- dimethylamino-butyric acid or 5-dimethylamino-pentanoic acid.
• the diacyl glycerol may comprise medium chain or long chain saturated or unsaturated fatty acids or derivatives or modifications thereof.
• the ionizable cationic ester of a sterol is preferably an ester of sterol coupled at the hydroxyl group to a tertiary amine with a carboxy group such as a compound with the formula (CH3)2N(CH2) n COOH, wherein n is an integer of 1 or more, , for instance n is 1 to 12; for example 3-dimethylamino-propionic acid or 4-dimethylamino-butyric acid or 5 dimethylamino-pentanoic acid.
• the sterol may be cholesterol, stigmasterol or - sitosterol.
• a carboxy compound is presented with the formula (CH 3 ) 2 N(CH 2 )nCOOH, wherein n is an integer of 1 or more.
• This carboxy compound comprises a guanidine group instead of a tertiary amine group.
• the ionizable cationic lipid can for example be selected from the molecules as according to Formulas (I) to (V).
• Formula (I) represents a tri-glyceride, wherein the ionizable cationic group (ICG) is comprised in the 1-position.
• Formula (II) represents the same type of tri-glyceride as represented in Formula (I), albeit that the molecule is stereo-specifically defined in the naturally occurring configuration, i.e. as it would in a phospholipid: the ICG group is in the same position as the phosphate group is in a phospholipid.
• Formula (III) represents a tri-glyceride, wherein the ionizable cationic group (ICG) is comprised in the 2-position.
• Formula (IV) represents a di-ester (or a tri-ester), wherein the ionizable cationic group (ICG) is connected via the amide functionality.
• Formula (V) represents a cholesteryl ester, wherein the ionizable cationic group (ICG) is connected via the ester functionality.
• the ionizable cationic group (ICG) is connected via the wavy bond to the rest of the molecule for any of the Formulas (I) to (V), where the ICG can either represent a tertiary amine (ICG type A, or ICG-A) or it can represent a guanidine (ICG type B, or ICG-B).
• Ri can be independently selected for every position, and it represents a linear or branched C1-C19 alkyl, a linear or branched C1-C19 alkenyl, aryl, arylene-alkyl or alkylene-aryl group, wherein said alkyl or alkenyl group, optionally containing 5 heteroatoms, independently selected from O and N.
• every Rigroup within a specific molecule as according to any of the Formulas (I) to (IV) is the same Ri group.
• the Ri group is a linear or branched C5-C19 alkyl group, or a linear or branched C5-C19 alkenyl group.
• Ri is an alkenyl group
• this group preferably has one single double bond only. More preferably, the Ri group is a linear or branched C9-C17 alkyl group or a linear or branched C5-C17 alkenyl group.
• R1 is a linear C5-C15 alkyl group or a linear C17-C19 alkenyl.
• Carboxylic acids derived from Ri i.e. Ri-COOH, are preferably naturally occurring fatty acid molecules such as capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, palmiteic acid, oleic acid or linoleic acid.
• Preferred are the C10-C16 saturated fatty acids as well as oleic acid (C18, unsaturated).
• the integer p is a discrete number and not an average value; p can be 0 to 11 .
• p is 0, 1 , 2, 3, 4, 5, 6, 7, 8 or 9. More preferably, p is 1 , 2, 3 or 4.
• the R2 group in Formula (IV) can be selected from a hydrogen, a methyl, an ethyl and a -CH2-O-C(O)-Ri a group (wherein Ri a has the same meaning as Ri defined above).
• R2 is a hydrogen, a methyl or a -CH2-O-C(O)-RI group. More preferably, R2 is a methyl.
• R3 group in Formula (IV) can be selected from a hydrogen, aryl, arylenealkyl, alkylene-aryl or a linear C1-C6 alkyl group.
• R3 is a hydrogen or a methyl. More preferably, R3 is a hydrogen.
• the R x group in ICG-A can be independently selected for every position, and is selected from a methyl, an ethyl, a propyl and an ethylene-hydroxy (-CH2-CH2-OH) group, preferably it is a methyl group.
• both R x groups in ICG-A are the same groups, and they preferably are methyl groups.
• the R y group in ICG-B can be independently selected for every position from a hydrogen, a linear or branched C1-C18 alkyl, aryl, arylene-alkyl or alkylene-aryl group, wherein said alkyl group optionally contains up to 5 heteroatoms, independently selected from O and N.
• the R y group is selected from a hydrogen and a linear C1-C6 alkyl group. Even more preferably, the R y group is a hydrogen.
• all four R y -groups in ICG-B are the same groups, and they preferably are hydrogens.
• Formulas (I), (II) and (IV) are preferred. More preferred are Formulas (I) and (II).
• ICG-A is preferred, i.e. tertiary amine ionizable cationic lipids are preferred.
• the ionizable cationic lipid molecule as according to any one of the Formulas (I) to (V) has a molecular weight that is higher than 250 Dalton, preferably higher than 350 Dalton, more preferably higher than 450 Dalton. It has a molecular weight that is lower than 3000 Dalton, preferably lower than 1800 Dalton, more preferably lower than 1200 Dalton.
• the molecules that are represented by Formulas (I) to (V) may exist in various isomeric forms such as rotamers, tautomers, stereoisomers or regiomers, and all of these are included in the scope of the present invention.
• the ionizable cationic lipid as according to any one of the Formulas (I) to (V) preferably is a single compound, i.e. not a mixture of compounds. Accordingly, the purity of the ionizable cationic lipid of Formula (I) to (V) preferably is 50% or higher, preferably 80% or higher, more preferably 90% or higher, most preferably 95% or higher. In case the ionizable cationic lipid is a mixture of compounds, then this is preferably due only to the presence of undefined stereo-centers in the molecule.
• An example is the use of branched alkyl chains in the ionizable cationic lipid that are of racemic origin. Other examples are tri-glycerides wherein the substitution pattern over the three hydroxygroups in the glycerol entity is not stereo-specifically defined.
• the ionizable cationic lipid is a molecule according to any one of Formulae (I), (II), (III), (IV) or (V) wherein ICG is or , wherein the wavy line indicates the point of attachment to the compound of formulae (I), (II), (III), (IV) or (V); p is an integer selected from 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11 ; each Ri is independently selected from the group consisting of linear or branched C1- C19 alkyl, linear or branched C1-C19 alkenyl, aryl, arylene-alkyl and alkylene-aryl group, wherein said alkyl or alkenyl group optionally contains up to 5 heteroatoms, independently selected from O and N;
• R2 is selected from the group consisting of hydrogen, methyl, ethyl and a -CH2-O-C(O)- Ri a ;
• R3 is selected from the group consisting of hydrogen, aryl, arylene-alkyl, alkylene-aryl and linear C1-C6 alkyl group;
• Ria is selected from the group consisting of linear or branched C1-C19 alkyl, linear or branched C1-C19 alkenyl, aryl, arylene-alkyl and alkylene-aryl group, wherein said alkyl or alkenyl group optionally contains up to 5 heteroatoms, independently selected from O and N; each R x is independently selected from the group consisting of methyl, ethyl, propyl and -CH2-CH2-OH; each R y group is independently selected from the group consisting of hydrogen, linear or branched 01-018 alkyl, aryl, arylene-alkyl or alkylene-aryl group, wherein said alkyl group optionally contains up to 5 heteroatoms, independently selected from O and N; or rotamers, tautomers stereoisomers or regioisomers thereof.
• alkyl by itself or as part of another substituent refers to a hydrocarbyl group of formula C n H2n+i wherein n is a number greater than or equal to 1.
• Alkyl groups may be linear or branched and may be substituted as indicated herein.
• alkyl groups of this invention comprise from 1 to 18 carbon atoms, preferably from 1 to 17 carbon atoms, preferably from 1 to 15 carbon atoms, preferably from 1 to 6 carbon atoms, preferably from 1 to 5 carbon atoms, preferably from 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms, still more preferably 1 to 2 carbon atoms.
• Ci-ealkyl refers to a hydrocarbyl group of formula -C n H2n+i wherein n is a number ranging from 1 to 6.
• “Ci-ealkyl” includes all linear or branched alkyl groups with between 1 and 6 carbon atoms, and thus includes methyl, ethyl, n-propyl, i-propyl, butyl and its isomers (e.g.
• n-butyl, i-butyl and t-butyl include all includes all linear or branched alkyl groups with between 1 and 5 carbon atoms, and thus includes methyl, ethyl, n-propyl, i-propyl, butyl and its isomers (e.g. n-butyl, i-butyl and t-butyl); pentyl and its isomers.
• Ci-4alkyl includes all linear or branched alkyl groups with between 1 and 4 carbon atoms, and thus includes methyl, ethyl, n-propyl, i-propyl, butyl and its isomers (e.g. n-butyl, i-butyl and t-butyl).
• Ci-3alkyl includes all linear or branched alkyl groups with between 1 and 3 carbon atoms, and thus includes methyl, ethyl, n-propyl, i-propyl.
• alkylene When the suffix "ene” is used in conjunction with an alkyl group, i.e. “alkylene”, this is intended to mean the alkyl group as defined herein having two single bonds as points of attachment to other groups.
• Ci-ealkylene by itself or as part of another substituent, refers to Ci-ealkyl groups that are divalent, i.e., with two single bonds for attachment to two other groups.
• Alkylene groups may be linear or branched and may be substituted as indicated herein.
• Non-limiting examples of alkylene groups include methylene (-CH2-), ethylene (-CH2-CH2-), methylmethylene (-CH(CHs)- ), 1-methyl-ethylene (-CH(CH3)-CH2-), n-propylene (-CH2-CH2-), 2- methylpropylene (-CH2-CH(CH3)-CH2-), 3-methylpropylene (-CH2-CH2-CH(CH3)-), n- butylene (-CH2-CH2-CH2-CH2-), 2-methylbutylene (-CH2-CH(CH 3 )-CH2-CH 2 -), 4- methylbutylene (-CH2-CH2-CH2-CH(CH3)-), pentylene and its chain isomers, hexylene and its chain isomers.
• alkenyl refers to an unsaturated hydrocarbyl group, which may be linear, or branched, comprising one or more carboncarbon double bonds.
• the subscript refers to the number of carbon atoms that the named group may contain.
• C2-6alkenyl refers to an unsaturated hydrocarbyl group, which may be linear, or branched comprising one or more carbon-carbon double bonds and comprising from 2 to 6 carbon atoms.
• C2-4alkenyl includes all linear, or branched alkenyl groups having 2 to 4 carbon atoms.
• C2-ealkenyl groups are ethenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and its isomers, 2-hexenyl and its isomers, 2,4-pentadienyl, and the like.
• aryl refers to a polyunsaturated, aromatic hydrocarbyl group having a single ring (i.e. phenyl) or multiple aromatic rings fused together (e.g. naphthyl), or linked covalently, typically containing 6 to 24 carbon atoms, preferably 6 to 12 atoms; preferably 6 to 10, wherein at least one ring is aromatic.
• Suitable aryl include Ce- aryl, more preferably Ce-saryl.
• C6-i2aryl comprise phenyl; biphenylyl; biphenylenyl; or 1-or 2-naphthanelyl;
• 1-, 2-, 3-, 4-, 5- or 6-tetralinyl also known as “1 ,2,3,4-tetrahydronaphthalene); 1-, 2-, 3- , 4-, 5-, 6-, 7- or 8-azulenyl, 4-, 5-, 6 or 7-indenyl, 4- or 5-indanyl, 5-, 6-, 7- or 8- tetrahydronaphthyl; 1 ,2,3,4-tetrahydronaphthyl; and 1 ,4-dihydronaphthyl; 1-, 2-, 3-, 4- or 5-pyrenyl.
• an aryl group i.e.
• arylene this is intended to mean the aryl group as defined herein having two single bonds as points of attachment to other groups.
• Suitable “C6-i2arylene” groups include 1 ,4- phenylene, 1 ,2-phenylene, 1 ,3-phenylene, biphenylylene, naphthylene, indenylene, 1-,
• heteroaryl ring may be selected from the group consisting of O, N, P and S; preferably O or N.
• alkylene-aryl as a group or part of a group, means a alkylene as defined herein, wherein at least one hydrogen atom is replaced by at least one aryl as defined herein.
• Alkylene-aryl groups typically contain 7 to 25 carbon atoms. Non-limiting examples of alkylene-aryl group include benzyl, phenethyl, dibenzylmethyl, methylphenylmethyl, 3-(2-naphthyl)-butyl, and the like.
• arylene-alkyl as a group or part of a group, means a arylene as defined herein, wherein at least one hydrogen atom is replaced by at least one alkyl group as defined herein.
• Arylene-alkyl groups typically contain 7 to 25 carbon atoms.
• Ester, amide, carboxylic acid and alcohol groups are defined hereunder, where Rp represents a hydrogen atom or a cyclic, linear or branched alkyl or alkylene groups. In groups that contain more than one Rp element, then these elements can be independently selected.
• An ester (functional) group or moiety as indicated in this document is to be understood as a group according to the formula: -C(O)-O-.
• An amide (functional) group or moiety as indicated in this document is to be understood as a group according to the formula: -NRp-C(O)-.
• a carboxylic acid (functional) group or moiety as indicated in this document is to be understood as a moiety or group according to the formula: -C(O)OH.
• the ionizable cationic lipids as according to any one of the Formulas (I) to (V) can be prepared by synthetic methods that are known in the art, such as without limitation as described in WO/2022/268913, such as in particular in the Examples section and especially Example 9 of WO/2022/268913.
• the (ionizable) cationic lipid preferably can be processed from solutions. Accordingly, the (ionizable) cationic lipid is preferably soluble in solvents ranging in polarity. Therefore, the (ionizable) cationic lipid is preferably soluble in tricaprylin, in ethanol or in iso-propanol, more preferably in all three of these solvents.
• the solubility can be checked by stirring about 20 mg of the (ionizable) cationic lipid in about 1 gram of tricaprylin, ethanol or iso-propanol, and assessing whether all material spontaneously dissolves to create a clear/transparent solution with a concentration of about 2 w/w%. The test can be done at about 20 °C (room temperature) or at about 37 °C.
• the (ionizable) cationic lipid is soluble at room temperature.
• the (ionizable) cationic lipid is preferably non-toxic, or it may have a limited and low toxicity, either on its own, or when bound to or tested together with nucleic acids, or assayed in the nanoparticle as taught herein.
• Toxicity cell tests can be executed by methods that are known in the art, such as for example by cell viability MTT assays, or by similar or comparable tests.
• the amount of the modified apolipoprotein in particular the cumulative amount in case of two or more modified apolipoproteins, ranges from 0.08 to 2.0 mol%, such as from 0.10 to 2.0 mol%; and/or the amount of phospholipid ranges from 5 to 90 mol%, such as from 15 to 90 mol%; and/or the amount of sterol ranges from 2.5 to 65 mol%, such as from 2.5 to 50 mol%; and/or the amount of cationic or ionizable cationic lipid ranges from 5.0 to 80 mol%, such as from 8.0 to 80 mol%, wherein the molar percentage is based solely on the combined amounts of the modified apolipoprotein, phospholipids, sterols and cationic or ionizable cationic lipids in the lipid nanoparticle.
• a nanoparticle includes two or more distinct apolipoprotein components, such as an apolipoprotein and a modified apolipoprotein, or two or more modified apolipoproteins and optionally one or more apolipoprotein, etc.
• the cumulative amount of these apolipoprotein components is taken into account when quantitative relationships to other constituents of the nanoparticle are discussed.
• the amount of modified apolipoprotein ranges from 0.05 to 2.0 mol%, such as from 0.10 to 2.0 mol% or from 0.08 to 0.5 mol%; and/or the amount of phospholipid ranges from 5 to 90 mol%, such as from 15 to 90 mol% or from 8.0 to 50 mol%; and/or the amount of sterol ranges from 2.5 to 65 mol%, such as from 2.5 to 50 mol% or from 4 to 65 mol%; and/or the amount of cationic or ionizable cationic lipid ranges from 5.0 to 80 mol%, such as from 8.0 to 80 mol% or from 5 to 65 mol% wherein the molar percentage is based solely on the combined amounts of the modified apolipoprotein, phospholipids, sterols and cationic and/or ionizable cationic lipid
• the amount of modified apolipoprotein ranges from 0.01 to 2.0 mol%, such as from 0.05 to 1.0 mol%, or from 0.05 to 0.5 mol%, or from 0.05 to 0.4 mol%, or from 0.05 to 0.3 mol%, or from 0.05 to 0.2 mol%, or from 0.05 to 0.1 mol%, such as about 0.06, about 0.07, about 0.08, or about 0.09 mol%; and/or the amount of phospholipid ranges from 2 to 90 mol%, such as from 2 to 80 mol%, or from 2 to 70 mol%, or from 2 to 60 mol%, or from 2 to 50 mol%, or from 2 to 40 mol%, or from 2 to 30 mol%, or from 2 to 20 mol%, such as from 5 to 10 mol%, such as about 6, about 7, about 8, or about 9 mol
• the amount of the modified apolipoprotein ranges from 0.1 to 90 weight%; the amount of nucleic acid ranges from 0.01 to 90 weight%; the amount of phospholipid ranges from 0.1 to 95 weight%; the amount of sterol ranges from 0.1 to 95 weight%; and/or the amount of cationic and/or ionizable cationic lipid ranges from 0.1 to 95 weight%, wherein these weight percentages are based on the combined amounts of the modified apolipoprotein, the nucleic acid, the phospholipid, the sterol and the cationic and/or ionizable cationic lipid.
• the amount of the apolipoprotein (in case of two or more modified apolipoproteins, cumulatively) ranges from 0.2 to 50 weight%, such as from 3 to 20 weight% or from 4 to 20 weight%, more preferably from 0.5 to 30 weight%, more preferably from 1 to 20 weight%.
• the amount of nucleic acid ranges from 0.02 to 30 weight%, more preferably from 0.05 to 20 weight%, more preferably from 0.1 to 15 weight%, such as from 0.5 to 5 weight%.
• the amount of phospholipid ranges from 0.2 to 60 weight%, more preferably from 1 to 50 weight%, such as from 10 to 50 weight%, more preferably from 3 to 40 weight%, such as from 10 to 40 weight%.
• the amount of sterol ranges from 0.2 to 90 weight%, more preferably from 0.5 to 70 weight%, such as from 2 to 65 weight%, more preferably from 1 to 50 weight%, such as from 2 to 45 weight%, from 10 to 45 weight% or from 10 to 20 weight%.
• the amount of cationic and/or ionizable cationic lipid ranges from 0.2 to 90 weight%, more preferably from 0.5 to 80 weight%, more preferably from 1 to 70 weight%, such as from 5 to 60 weight%, from 8 to 60 weight%, from 9 to 60 weight%, from 10 to 60 weight%, from 15 to 25 weight%, or from 20 to 60 weight%.
• the amount of optional filler or filler molecule ranges from 0 to 90 weight%, more preferably from 0 to 80 weight%, more preferably from 0 to 70 weight%, such as from 0 to 65 weight%.
• the amount of optional filler or filler molecule ranges from 20 to 80 weight%, more preferably from 30 to 70 weight%, even more preferably from 30 to 65 weight%, such as from 40 to 65 weight%, from 45 to 55 weight% or from 30 to 60 weight%.
• weight percentages as indicated above are based on the combined amounts of the modified apolipoprotein, the nucleic acid, the phospholipid, the sterol and the cationic and/or ionizable cationic lipid, and optionally the filler material, i.e. these five or six components add up to 100% of the weight of the nanoparticle in the context of these statements. These weight percentage ranges contribute positively to the stability of the nanoparticles and their ability to incorporate nucleic acids.
• the nanoparticle as taught herein does not comprise a filler or filler molecule.
• the ratio of the modified apolipoprotein (in case of two or more modified apolipoproteins, cumulatively) to phospholipid based on percentage molar weight is between 1 :25 and 1 :400, more preferably between 1 :50 and 1 :200, even more preferably between 1 :75 and 1 :150.
• the ratio of the modified apolipoprotein (in case of two or more modified apolipoproteins, cumulatively) to phospholipid based on weight is from 2:1 to 1 :10, more preferably from 1 :1 to 1 :5, even more preferably from 1 :1.5 to 1 :4.
• the payload may be a small organic compound such as a small molecule drug.
• the small organic compound is synthesized.
• the therapeutic may for example be an anticancer therapy such as a chemotherapy.
• the payload may be a biologic.
• the term biologic is used to indicate a biopharmaceutical, also known as a biologic(al) medical product, and can be any pharmaceutical drug product manufactured in, extracted from, or semi-synthesized from biological sources. Biologies can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues.
• the lipid nanoparticle has an average size of 10 to 100 nm, such as from 30 to 100 nm.
• the ratio of modified apolipoprotein (in case of two or more modified apolipoproteins, cumulatively) to phospholipid based on percentage molar weight is between 1 :25 and 1 :400, more preferably between 1 :50 and 1 :200, even more preferably between 1 :75 and 1 :150.
• the ratio of modified apolipoprotein (in case of two or more modified apolipoproteins, cumulatively) as taught herein to phospholipid based on percentage molar weight is between 1 :25 and 1 :400, more preferably between 1 :50 and 1 :200, even more preferably between 1 :75 and 1 :150.
• the ratio of modified apolipoprotein (in case of two or more modified apolipoproteins, cumulatively) to phospholipid based on weight is from 3:1 to 1 :100. In particular embodiments, the ratio of modified apolipoprotein (in case of two or more modified apolipoproteins, cumulatively) as taught herein to phospholipid based on weight is from 3:1 to 1 :100.
• the amount of the modified apolipoprotein ranges from 0.05 to 2.0 mol%, such as from 0.1 to 1.0 mol%, for example from 0.2 to 0.7 mol%, or from 0.2 to 0.5 mol%, such as preferably about 0.3 mol%; and/or the amount of phospholipid ranges from 5 to 90 mol%, such as from 10 to 50 mol%, for example from 10 to 40 mol%, from 10 to 30 mol%, or from 10 to 20 mol%, such as about 11 , about 12, about 13, about 14, about 15, about 16, about 17, about 18, or about 19 mol%; and/or the amount of sterol ranges from 2.5 to 65 mol%, such as from 2.5 to 60 mol%, from 2.5 to 50 mol%, from 2.5 to 40 mol%, or from
• the invention relates to a method of manufacturing a lipid nanoparticle as described herein, the method comprising the steps of: a1) expressing and isolating a modified apolipoprotein as disclosed herein to obtain an isolated modified apolipoprotein; and/or a2) chemically conjugating a targeting body to an apolipoprotein or apolipoprotein mimetic to obtain a modified apolipoprotein and isolating the modified apolipoprotein; b) combining the isolated modified apolipoprotein obtained in step a1 and/or step a2 with phospholipids, sterols and optionally lipids to obtain a lipid nanoparticle.
• step b) comprises: b1) mixing, preferably rapid mixing, of lipid components in organic solvent with a nucleic acid in an aqueous buffer to produce nanoparticles, wherein the lipid components comprise a phospholipid, a sterol, a core component, and optionally a lipid; and wherein the aqueous buffer has a pH of 5.5 or lower, preferably 5.0 or lower; and b2) mixing, preferably rapid mixing, of lipid nanoparticles with the modified apolipoprotein to produce the nanoparticle at a pH between 5.5 and 9.0, preferably at a pH between 6.0 and 8.0, more preferably at a pH between 6.5 and 8.0.
• the modified apolipoprotein can be expressed as a chimeric fusion protein of the apolipoprotein with the targeting body or can be chemically conjugated to the targeting body or can be produced be a combination of these.
• Expression of chimeric proteins is known to the skilled person and can be used when the targeting body is a peptide or protein. It is well within the knowledge of the skilled person to use molecular techniques to produce a nucleic acid encoding such protein, for example by cloning targeting body encoding sequence in frame with an apolipoprotein (or mimetic or derivative) encoding sequence, for example at C or N terminal sequence encoding nucleotides.
• An advantage of using chimeric protein expression is that all expressed protein will be fusion protein.
• chemical conjugation may be used.
• Suitable methods for chemical conjugation of the targeting body to the apolipoprotein (or mimetic thereof) are known to the skilled person. Non limiting examples are strain promoted cycloaddition, aminolysis and Michael type addition.
• an existing or introduced cysteine residue may be used on either the apolipoprotein or the targeting body. Introduction of a cysteine residue may be achieved by point mutation of a nucleotide in the encoding nucleotide sequence, or by introduction of a cysteine encoding codon.
• An advantage of chemical conjugation is that it is not limited to the use of peptide or protein sequences but can be applied to any type of organic molecule.
• modified apolipoprotein, phospholipids, sterols and optional components may be rapidly mixed to obtain a lipid nanoparticle.
• Optionally added may be lipids and/or a payload as defined herein.
• the present invention also encompasses a method for producing a lipid nanoparticle, comprising the step of: a) rapid mixing of lipid components in organic solvent with a nucleic acid in an aqueous buffer to produce lipid nanoparticles, wherein the lipid components comprise a phospholipid, a sterol, a cationic lipid or ionizable cationic lipid, wherein the aqueous buffer has a pH of 5.0 or lower; and b) rapid mixing of the lipid nanoparticles with one or more modified apolipoprotein as taught herein; to produce the lipid nanoparticle at a pH between 5.5 and 8.0, preferably between 6.0 and 8.0.
• a two-step reaction is performed, where in the first step, a nucleic acid containing nanoparticle is formed, and in the next second step, modified apolipoprotein is included in the nanoparticle.
• the first step is performed at low pH and the second step is performed at physiological pH.
• the organic solvent may be an alcohol such as ethanol, iso-propanol, methanol, acetonitrile, dimethyl sulfoxide (DMSO), chloroform or combinations thereof.
• Preferred organic solvents are water mixable and non-toxic, for example ethanol and DMSO, or combinations thereof.
• the organic solvent may be from 96% to 100% of ethanol, preferably 100% ethanol. Rapid mixing is known in the field and has for example been described in Hirota et al. BIOTECHNIQUES VOL. 27, NO. 2, p286-289; Jeffs et al., Pharm Res 22, 362- 372 (2005); Kulkarni et al., ACS Nano 2018, 12, 5, 4787-4795
• the aqueous buffer in step a) has a low pH to ensure that the ionizable cationic lipid is positively charged, allowing binding within and inclusion of the nucleic acid I cationic lipid complex in the particle.
• the buffer may have a pH of 5.0 or lower, such as 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1 , 4.0, 3.9, 3.8, 3.7, 3.6, 3.5 or lower.
• the aqueous buffer may be any buffer that does not damage the nucleic acid.
• An exemplary buffer is sodium acetate at pH 4.0.
• the nanoparticle is then taken in an aqueous buffer with a pH of around 6 to 8, preferably 7 to 8 more preferably around 7.4.
• aqueous buffer in the indicated pH range.
• aqueous buffer suitable for this step is 155 mM PBS at pH 7.4, but it is understood that any buffer may be used that does not damage the nucleic acid.
• step b) the nanoparticle in an aqueous buffer at pH between 6 to 8, preferably between pH 7 to 8, is rapidly mixed with the modified apolipoprotein in an aqueous buffer at pH between 5.5 to 8, preferably 6 to 8, more preferably between pH 7 to 8, to obtain the nanoparticles.
• nucleic acid-containing nanoparticles with a broad set of desired and beneficial characteristics (stability, low toxicity or non-toxicity, high nucleic acid retention, nucleic acid activity, etc.).
• desired and beneficial characteristics such as low toxicity or non-toxicity, high nucleic acid retention, nucleic acid activity, etc.
• the described formulation method is non-limiting as other processes may also lead to nanoparticles with beneficial features.
• a further aspect of the invention provides a pharmaceutical composition
• a pharmaceutical composition comprising the modified apolipoprotein as taught herein, the nucleic acid as taught herein or the lipid nanoparticle as taught herein, and a pharmaceutically acceptable carrier.
• the invention relates to modified apolipoprotein as defined herein or the lipid nanoparticle as defined herein, or the lipid nanoparticle obtained or obtainable by the method as described herein, or the nucleic acid as defined herein, or the pharmaceutical composition as defined herein for use as a medicament. It is envisioned that either the modified apolipoprotein (e.g. by the action of an attached payload) or the payload comprised in the nanoparticle may be used to treat, ameliorate or alleviate a symptom in a subject.
• an immune related disorder such as transplantation rejection, graft-versus-host disease (GVH), atherosclerosis, infection, inflammation, auto-immunity, allergy, cancer, a genetic disorder, a metabolic disorder, a neurological disorder or tissue trauma, preferably an immune related disorder such as transplantation rejection, atheros
• An immune related disorder as used herein comprises any disorder wherein the immune system plays a role in the disease development.
• An immune related disorder may refer to a disorder where the immune system is suppressed or where it is (over)activated.
• immune related disorders are cancer, infection, sepsis, autoimmune diseases, and cardiovascular diseases.
• autoimmune diseases are Type 1 diabetes, Rheumatoid arthritis (RA), Psoriasis/psoriatic arthritis, Multiple sclerosis (MS), Systemic lupus erythematosus (SLE), Inflammatory bowel disease (IBD), Addison’s disease, Graves’ disease, Sjogren’s syndrome, Hashimoto’s thyroiditis, Myasthenia gravis, Autoimmune vasculitis, Pernicious anemia, and Celiac disease.
• RA Rheumatoid arthritis
• MS Multiple sclerosis
• SLE Systemic lupus erythematosus
• IBD Inflammatory bowel disease
• Addison’s disease Graves’ disease
• Sjogren’s syndrome Hashimoto’s thyroiditis
• Myasthenia gravis Autoimmune vasculitis
• Pernicious anemia and Celiac disease.
• the immune related disorder is selected from the group consisting of transplantation rejection, graft-versus-host disease (GVH), atherosclerosis, infection, inflammation, auto-immunity, allergy, cancer, a genetic disorder, a metabolic disorder, a neurological disorder and tissue trauma, preferably transplantation rejection, atherosclerosis, infection, auto-immunity, cancer, a genetic disorder, a metabolic disorder, a neurological disorder or tissue trauma
• the immune related disorder is selected from the group consisting of cancer, infection, sepsis, Type 1 diabetes, Rheumatoid arthritis (RA), Psoriasis/psoriatic arthritis, Multiple sclerosis (MS), Systemic lupus erythematosus (SLE), Inflammatory bowel disease (IBD), Addison’s disease, Graves’ disease, Sjogren’s syndrome, Hashimoto’s thyroiditis, Myasthenia gravis, Autoimmune vasculitis, Pernicious anemia, and Celiac disease.
• RA Rheumatoid arthritis
• MS Multiple sclerosis
• SLE Systemic lupus erythematosus
• IBD Inflammatory bowel disease
• Addison’s disease Graves’ disease
• Sjogren’s syndrome Hashimoto’s thyroiditis
• Myasthenia gravis Autoimmune vasculitis
• Pernicious anemia and Celiac disease.
• the invention relates to the use of a modified apolipoprotein as described herein or the lipid nanoparticle according as described herein, or the lipid nanoparticle obtained or obtainable by the method as described herein, or the nucleic acid as defined herein, or the pharmaceutical composition as defined herein in delivering a payload (e.g.
• the target is a cell, tissue, and/or organ, even more preferably wherein the target is a lymphoid cell, a myeloid cell, a tumor cell, or wherein the targeting body binds a bacterial, viral, fungal or parasitic protein or antigen, preferably wherein the lymphoid or myeloid cell is selected from: a monocyte, a macrophage, an M1-like macrophage, an M2-like macrophage, an eosinophil, a basophil, a mast cell, an NK cell, a B cell, a plasma cell, a regulatory T cell, a hematopoietic stem cell, a T helper cell such as Th1 , Th2, Th17 or Th22, a dendritic cell, such as a plasmacytoid dendritic cell, a conventional DC 1 or a conventional DC 2, or a tumor-associated macrophage.
• the lymphoid or myeloid cell is selected from: a monocyte, a macrophag
• the use is an ex vivo or in vitro use.
• the use is an in vivo use.
• the apolipoprotein or targeting body will bind to a cell surface protein, such as a receptor. Therefore, the target may be a protein such as a receptor, a cell or cell type (expressing said protein), a tissue or tissue type (expressing said protein) or an organ (expressing said protein). It is understood that by choosing or adapting the targeting body the modified apolipoprotein can be targeted to different proteins. For example, the receptor binding domain of a ligand can be used to target a specific receptor. Alternatively known binding partners of cell surface proteins can be used to reroute the fusion protein (i.e. the modified apolipoprotein).
• a further aspect of the invention provides an in vitro or ex vivo method for introducing a nucleic acid in a cell, the method comprising contacting the nucleic acidcontaining lipid nanoparticle as taught herein, or the nucleic acid-containing lipid nanoparticle obtained or obtainable by the method as taught herein, with a cell.
• a further aspect of the invention provides an in vivo method for introducing a nucleic acid in a cell, the method comprising contacting the nucleic acid-containing lipid nanoparticle as taught herein, or the nucleic acid-containing lipid nanoparticle obtained or obtainable by the method as taught herein, with a cell.
• a further aspect of the invention provides the nucleic acid-containing lipid nanoparticle as taught herein, or the nucleic acid-containing lipid nanoparticle obtained or obtainable by the method as taught herein, for use in the in vivo delivery of a nucleic acid to a subject.
• a further aspect of the invention provides a method for the in vivo delivery of a nucleic acid, the method comprising administering the nucleic acid-containing lipid nanoparticle as taught herein, or the nucleic acid-containing lipid nanoparticle obtained or obtainable by the method as taught herein, to a subject.
• a further aspect of the invention provides a method for treating a disease or disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of the nucleic acid-containing lipid nanoparticle as taught herein, or the nucleic acid-containing lipid nanoparticle obtained or obtainable by the method as taught herein, to the subject.
• the diseases may be any of the diseases as discussed herein, such as for example an immune related disorder such as transplantation rejection, graft-versus- host disease (GVH), atherosclerosis, infection, inflammation, auto-immunity, allergy, cancer, a genetic disorder, a metabolic disorder, a neurological disorder or tissue trauma, preferably transplantation rejection, atherosclerosis, infection, auto-immunity, cancer, a genetic disorder, a metabolic disorder, a neurological disorder or tissue trauma.
• an immune related disorder such as transplantation rejection, graft-versus- host disease (GVH), atherosclerosis, infection, inflammation, auto-immunity, allergy, cancer, a genetic disorder, a metabolic disorder, a neurological disorder or tissue trauma, preferably transplantation rejection, atherosclerosis, infection, auto-immunity, cancer, a genetic disorder, a metabolic disorder, a neurological disorder or tissue trauma.
• an immune related disorder such as transplantation rejection, graft-versus- host disease (GVH), atherosclerosis, infection, inflammation, auto-
• a purpose of the nucleic acid-containing nanoparticles described herein is to deliver a nucleic acid to a cell or to deliver a nucleic acid therapy to a subject.
• the nucleic acid may be for example an mRNA encoding a peptide or protein of interest which is to be expressed in the cell, or may comprise a short nucleic acid such as an siRNA, shRNA intended to interfere in gene expression (e.g. gene silencing), or it may comprise a component of the CRISPR-Cas or a related gene editing system (e.g. gRNA) to induce a mutation in the genome of the cell. Therefore in general the mode of action of the nucleic acid (the payload of the nanoparticle) is in the cytoplasm or the nucleus. Therefore the nanoparticle preferably has at least the following properties: 1) it allows targeting of the intended target cell, and 2) it allows delivery of the payload where it can assert its action (thus in most cases in the cytoplasm or nucleus of the target cell).
• the nucleic acid therapy comprising nanoparticles may be administered to a subject in need thereof.
• the administration may be parenteral, e.g. intravenous, intramuscular or subcutaneous.
• the administration may further be oral, sublingual, topical, rectal, nasal (inhaled) or vaginal.
• the targeting of the target tissue or cells is determined by the proper choice of the modified apolipoprotein.
• the use of the nanoparticle or composition comprises delivering a nucleic acid to the myeloid compartment or the spleen. This may for example be achieved by intravenous parenteral administration.
• the nanoparticles of certain embodiments of the invention after systemic injection, can target tissues (spleen, bone marrow) that are associated with the presence of immune cells.
• nucleic acid-containing nanoparticle as taught herein, or the composition as taught herein for use in immunotherapy are provided.
• the invention relates to the nanoparticle, including the nucleic acid containing nanoparticles, as taught herein, or the composition comprising them for use in the treatment of a disease by stimulating or inhibiting an innate immune response, preferably wherein said disease is a disease that would benefit from stimulating or inhibiting the innate immune response in a subject, such as a disease characterized by a defective innate immune response, more preferably wherein said disease to be treated is a cancer, a cardiovascular disease, an autoimmune disorder or xenograft rejection. Therefore the nanoparticles may be used in the treatment of any disease relating the immune system such as any immune disorder, or for the treatment of any disease or disorder where modulating the immune response is deemed a viable treatment option.
• the invention relates to a nucleic acid encoding a fusion protein (i.e. modified apolipoprotein) as defined herein.
• the nucleic acid may be comprised in a vector such as a viral vector for stable integration in a cell, or an expression vector to enable transient expression.
• aNPs are lipid-based nano-sized formulations (diameter -30-200 nm) with a hydrophobic core and apolipoproteins covering the outer surface.
• Apolipoproteins are helical proteins with inherent affinity for lipid layers due to their amphiphilic character.
• the presence of apolipoprotein modulates the biological behaviour of the aNP. For example, apolipoprotein A1 interacts with cells via scavenger receptor class B type 1 (SRB1) and ATP-binding cassette transporter ABCA1.
• SRB1 scavenger receptor class B type 1
• ABCA1 ATP-binding cassette transporter
• aNP This increases interactions of the aNP with myeloid cells in lymphoid organs.
• therapeutically functionalized aNPs have shown to have little effect on immune cell types without these mentioned receptors.
• increasing targeting specificity within the myeloid compartment can also increase efficiency of the therapeutics. Re-routing aNPs to specific cell types would therefore increase the power of this modular platform.
• Nanobodies are single antigen specific polypeptides consisting of the variable domain of the heavy chain (VH domain) of heavy chain only antibodies found in camelids and are also called VHH domains or single-domain antibodies (sdAbs).
• VH domain variable domain of the heavy chain
• sdAbs single-domain antibodies
• the nanobodies are low in complexity and highly stable and soluble, giving them greater therapeutic potential compared to the human antibody equivalent. They consist of a conserved framework of p-sheets, and three variable complementarity determining regions (CDRs). A nanobody’s specificity arises from the variation in these CDR loops.
• Nanobodies lack the hydrophobic patch that is present in the framework of human antibodies to increase the interaction between the VH and VL domain. Nanobodies have four hallmark mutations in this region which are key for their stability and solubility.
• the conserved framework can be modified using point mutations to humanize the nanobodies to limit immunogenicity.
• Apolipoprotein-nanobody fusion proteins combine the particle forming ability of the apolipoprotein with the targeting ability of the nanobody. Fusion proteins are generated by molecular cloning of the genes for the apolipoprotein and the nanobody, which are fused with an appropriate amino acid linker to allow for sufficient space between the apolipoprotein and the nanobody. The fusion proteins will subsequently be recombinantly expressed in E. coli and purified using purification tags like a histidine tag. Including the fusion protein during aNP production then generates cell-type specific aNPs. The targeted cell type can easily be determined by changing the nanobody sequence to one specific for a desired cell marker.
• Nanobodies specific for desired cell markers are engineered via a yeast surface display method and directed evolution.
• Machine-learning-guided generative modelling is used to introduce variation in the directed evolution process to create nanobody sequences with higher affinity for their target. This process is repeated until a sequence is selected with the desired binding affinity.
• aNPs are incubated with human peripheral blood mononuclear cells (PBMCs) and flow cytometry is used to evaluate aNP binding to immune cells. After incorporation of a therapeutic compound, therapeutic efficacy of the aNP is assessed in vitro.
• PBMCs peripheral blood mononuclear cells
• Re-routed aNPs have the potential to specifically deliver therapeutic compounds to desired immune cell types, thereby modulating the immune response.
• a major advantage of the re-routed aNP platform technology is the possibility to easily exchange the nanobody and therapeutic payload.
• Re-routed aNPs can therefore be implemented as immunotherapies that promote the immune response to treat e.g., cancer or infectious diseases, or to dampen the immune response to treat e.g., autoimmune diseases or during organ transplantation.
• Example 4 Fusion proteins of an apolipoprotein fused to a rerouting protein or peptide (targeting body) and incorporation thereof into lipid nanoparticles
• VHHCD8-apoA 1 fusion protein A small culture of ClearColi cells transformed with pET20b-VHHCD8-apoA1 plasmid and pDiscoTune plasmid was started in LB medium with 100 pg/mL ampicillin. The next day, 40 mL of small culture was diluted in 1 liter of 2YT medium to start large cultures and rhamnose was added at a final concentration of 50 pM to induce T7 lysozyme on the pDiscoTune plasmid.
• the culture was grown at 37°C and 150 rpm until an OD600 of 0.6-0.8, then isopropyl - d-1 -thiogalactopyranoside (IPTG) was added at a final concentration of 0.1 mM to induce expression.
• IPTG isopropyl - d-1 -thiogalactopyranoside
• the induced culture was incubated overnight at 18°C and 150 rpm.
• Induced bacterial cultures were pelleted and cells were resuspended in lysis buffer (20 mM Tris, 500 mM NaCI, pH 7.9).
• Benzonase Nuclease Merck Millipore
• one completeTM EDTA-free Protease Inhibitor Cocktail tablet (Roche) per 50 mL cell suspension was added and the cell suspension was incubated at 4°C while stirring.
• the suspension was subsequently homogenized three times at 15000-20000 psi using the A vestin Emulsiflex C3.
• the cell lysate was kept on ice at all times.
• cell lysate was centrifuged to pellet insoluble cell debris and supernatant was flown through an Immobilized Metal Chelate Affinity Chromatography (IMAC) column containing immobilized nickel ions.
• the column was washed with 8 column volumes of buffer A (20 mM Tris, 500 mM NaCI, 10 mM imidazole, pH 7.9), then 8 column volumes of buffer A50 (20 mM Tris, 500 mM NaCI, 50 mM imidazole, pH 7.9).
• VHHCD8-apoA1 8 column volumes of buffer A500 (20 mM Tris, 500 mM NaCI, 500 mM imidazole, pH 7.9) was applied to the column. All fractions of the purification steps were collected and analyzed with SDS-PAGE. The buffer of fractions containing purified VHHCD8-apoA1 was changed to PBS using Amicon Ultracentrifugal Filters (Amicon). To store VHHCD8- apoA1 , aliquots were snap-frozen in liquid nitrogen and stored at -70°C.
• the VHHCD8-apoA1 fusion protein has the sequence as defined by SEQ ID NO: 1 , or is encoded by a sequence as defined by SEQ ID NO: 2, which comprises a linker between apoA1 and VHHCD8 comprising a cysteine.
• lipid nanoparticles from stock solutions (10 mg/mL) in chloroform, DMPC (128 pL), cholesterol (Sigma-Aldrich) (7.5 pL) and for spherical lipid nanoparticles: POPO (66.5 pL), PHPC (17.5 pL), cholesterol (4.5 pL), and tricaprylin (Sigma-Aldrich) (2.8 pL from 0.956 g/mL stock) were combined in a glass vial and dried under vacuum. The resulting film was redissolved in an acetonitrile/methanol mixture (95:5 weight%, 900 pL total volume).
• VHHCD8-apolipoprotein A1 protein in PBS 6.5 mL, 0.14 mg/mL
• Both solutions were simultaneously injected using a microfluidic pump fusion 100 (Chemyx Inc) into a Zeonor herringbone mixer (Microfluidic Chipshop) with a flow rate of 0.8 mL/minute for the lipid solution and a rate of 6 mL/minute for the apolipoprotein A1 solution.
• the obtained solution was concentrated by centrifugal filtration using either a 10 kDa MWCO for discoidal and a 50 kDa MWCO for spherical aNPs Vivaspin tube at 4000 rpm to obtain a volume of 1 mL.
• PBS (5 mL) was added, and the solution was concentrated to 1 ml; this was repeated twice.
• the washed solution was concentrated to approximately 1.5 ml and filtered through a 0.22 pm PES syringe filter to obtain the finished VHHCD8- apolipoprotein A1-containing nanoparticles.
• VHHCD8-apolipoprotein A1-containing nanoparticle formulations in PBS were filtered through a 0.22 pm PES syringe filter and analyzed by dynamic light scattering on a Malvern Zetasizer Nano ZS analyzer. Values are reported as the mean number average size distribution.
• Cryo-TEM First, the surface of 200-mesh lacey carbon supported copper grids (Electron Microscopy Sciences) was plasma treated for 40 seconds using a Cressington 208 carbon coater.
• VHHCD8-apolipoprotein A1-containing nanoparticles ⁇ 1 mg protein/ml
• 3 pl of VHHCD8-apolipoprotein A1-containing nanoparticles was applied on a grid and vitrified into a thin film by plunge vitrification in liquid ethane by using an automated robot (FEI Vitrobot Mark IV).
• Cryo-TEM imaging was performed on the cryoTITAN (Thermo Fisher Scientific), equipped with a field emission gun (FEG), a post-column Gatan imaging filter (model 2002) and a post-GIF 2k * 2k Gatan CCD camera (model 794).
• the images were acquired at 300 kV acceleration voltage in bright-field TEM mode with zero-loss energy filtering at either 6,500x (dose rate of 1.64 electrons/A2 s) or 24,000* magnification (dose rate of 11.8 electrons/A2 s), and 1s acquisition time.
• Spleens were obtained from mice, cut into pieces, and strained through a 70 pm strainer (Corning) multiple times to obtain a splenocyte suspension. Cells were spun down at 1500 rpm for 10 minutes, the supernatant was removed and the cells were dissolved in 2 mL 1X red blood cell lysis buffer (Thermofisher). Suspension was incubated at room temperature for 5 minutes, 10 mL Roswell Park Memorial Institute (RPMI) medium (Thermofisher) was added, and cells were again spun down at 1500 rpm for 10 minutes. Cells were then redissolved in RPMI medium and plated in a 96 wells plate at 150.000 cells/well.
• RPMI Roswell Park Memorial Institute
• the proteins were labeled by adding sulfo-cyanine5-maleimide (Lumiprobe) in dimethyl sulfoxide (DMSO) at a 5x molar excess. This mixture was incubated at room temperature for 2 hours. Excess dye was removed using a PD minitrap G-25 desalting column (Cytiva). Fluorescently labeled aNPs were formulated by adding 6.4 pg Dil for discoidal formulations and 21 pg Dil for spherical formulations.
• Fluorescently labeled fusion proteins or aNPs and controls were added to the wells and incubated for 30 minutes at 4 °C (for proteins) or 37 °C (for aNPs) after which cells were harvested, washed, and stained for CD3 and CD4 and measured on Cytoflex (Beckman Coulter Inc.). Flow cytometry data was analyzed using FlowJo software (BD).
• VHHCD8-apoA1 fusion protein was successfully expressed in Clearcoli cells. Minor protein contaminants were present after IMAC purification [lane E1] (Fig. 3). The most prominent band corresponds to the fusion protein with a molecular weight of 43.3 kDa (Fig. 3). The correct mass was later confirmed via mass spectrometry (data not shown).
• Discoidal apolipoprotein nanoparticles were formulated incorporating VHHCD8-apoA1 . Using Dynamic Light Scattering (DLS), the particles’ size and poly dispersity index (PDI) were determined. The size of the particles remained stable for 7 days (data not shown). On day 14 the size had increased slightly (data not shown). The PDI remained stable for 14 days (data not shown). Cryo-TEM images of the nanoparticles showed the expected discoidal shape (data not shown)
• VHHCD8-apoA1 and apoA1 were fluorescently labeled, and subsequently added to mouse splenocytes.
• VHHCD8-apoA1 fusion protein a dose dependent increase of Mean Fluorescence Intensity (MFI) was observed, indicating the binding of the fusion protein to the CD8 receptor (Fig. 4; lower panel).
• MFI Mean Fluorescence Intensity
• Discoidal and spherical aNPs were formulated with VHHCD8-apoA1 and apoA1.
• a fluorescent dye was integrated in the lipid structure of the particle.
• Mouse splenocytes were incubated with the nanoparticles.
• Both VHHCD8-apoA1 particles showed a dose dependent increase of MFI, indicating the binding of the nanoparticle to the CD8 receptor (Fig. 5).
• the discoidal nanoparticles showed a greater increase than the spherical nanoparticles. No increase in MFI was observed for the apoA1 nanoparticle conditions.
• Example 5 In vivo biodistribution of lipid nanoparticles comprising a fusion protein of an apolipoprotein fused to a rerouting protein or peptide
• VHHCD8-apoA1 protein SEQ ID NO:1
• PBS 6.5 mL, 0.14 mg/mL
• Both solutions were simultaneously injected using a microfluidic pump fusion 100 (Chemyx Inc) into a Zeonor herringbone mixer (Microfluidic Chipshop) with a flow rate of 0.8 mL/minute for the lipid solution and a rate of 6 mL/minute for the apoA1 solution.
• the obtained solution was concentrated by centrifugal filtration using a 50 kDa MWCO for spherical aNPs Vivaspin tube at 4000 rpm to obtain a volume of 1 mL.
• PBS (5 mL) was added, and the solution was concentrated to 1 ml; this was repeated twice.
• the washed solution was concentrated to approximately 1.5 ml and filtered through a 0.22 pm PES syringe filter to obtain the finished aNPs.
• VHHCD8-apolipoprotein A1 fusion protein nanoparticle composition in molar percentages.
• DiR 1 ,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine
• Lyso-PC 1- palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine
• POPC 1-palmitoyl-2-oleoyl-sn- glycero-3-phosphocholine.
• Spherical VHHCD8-aNPs with 2 mol% DiR (1 ,1 '-dioctadecyl-3, 3, 3', 3'- tetramethylindotricarbocyanine iodide) were intravenously injected in C57BL/6 mice at a dose of 1 mg/kg DiR. After 24 hours, mice were sacrificed, blood was harvested and after PBS perfusion other tissues of interest (bone marrow, spleen, and lymph nodes) were harvested.
• the tissues were homogenized into a single cell suspension, stained for myeloid (CD115, F4/80, Ly6C, CD11b, CD45, Ly6G, CD11c), lymphoid (CD45, CD11b, CD3, CD19, CD4, CD8a), and progenitor (CD117, CD34, Ly-6A/E, CD135, CD16/32, CD48, CD41 , CD150, CD3, CD11 b, CD45R/B220, Ly-76, Ly6G, Ly6C) cell markers, and analyzed on Cytoflex (Beckman Coulter Inc.). Flow cytometry data was analyzed using FlowJo software (BD).
• BD FlowJo software
• the spherical lipid nanoparticles containing VHHCD8-apolipoprotein A1 were characterized using DLS to determine their hydrodynamic size (number mean) and polydispersity index (Pdi), and cryogenic electron microscopy was used to determine their size and morphology (Fig. 6).
• VHHCD8-apolipoprotein A1 fusion protein nanoparticles associated significantly less with myeloid cells in the bone marrow, spleen, and blood when compared with control apolipoprotein A1 protein nanoparticles (Fig. 8A).
• VHHCD8-apolipoprotein A1 fusion protein nanoparticles associated significantly more with CD8+ T cells in the bone marrow, spleen, and blood when compared with control apolipoprotein A1 protein nanoparticles Fig. 8B.
• VHHCD8- apolipoprotein A1 fusion protein nanoparticles associated less with CD4+ T cells in the bone marrow, spleen, and blood when compared with control apolipoprotein A1 protein nanoparticles (Fig. 8C).
• VHHCD8-apolipoprotein A1 fusion protein nanoparticles associated more with CD3+ T cells in the bone marrow, spleen, and blood when compared with control apolipoprotein A1 protein nanoparticles (Fig. 8D).
• VHHCD8-apolipoprotein A1 fusion protein nanoparticles associated more with CD8+ or CD3+ when compared with control apolipoprotein A1 protein nanoparticles, and VHHCD8-apolipoprotein A1 fusion protein nanoparticles associated less with CD4+ T cells in the lymph nodes when compared with control apolipoprotein A1 protein nanoparticles (Fig. 9).
• VHHCD8-apolipoprotein A1 fusion protein nanoparticles associated with more CD8+ T cells in the bone marrow, blood, spleen, and lymph nodes when compared with control apolipoprotein A1 protein nanoparticles (Fig. 10). There was no difference in CD4+ T cell engagement between tretament groups (Fig. 10).
• Example 6 Lipid nanoparticles comprising fusion proteins of an apolipoprotein fused to a rerouting peptide or protein and/or fusion proteins of an apolipoprotein fused to an immunomodulatory biomolecule
• ApoA1-IL-2 was reduced to break disulfide bonds between the cysteines in the protein by incubation in 1 mM DTT at room temperature for 2 hours.
• ApoA1-IL-2 and VHHCD8- apoA1 were fluorescently labeled with cy3 and cy5, respectively, as described in Example 4.
• the apoA1-IL-2 fusion protein has the sequence as defined by SEQ ID NO: 3 or 5, or is encoded by a sequence as defined by SEQ ID NO: 4 or 6.
• Discoidal aNPs were formulated with 513 g apoA1-IL-2 and 467 pg VHHCD8-apoA1 .
• Spherical aNPs were formulated in two sizes, where only the triglyceride content was varied. Big spheres were formulated as described in Example 5, small spheres were formulated with half the triglyceride content of the big spheres. Spheres with only apoA1-IL-2 (donor) contained 1025 pg apoA1-IL-2. Spheres with only VHHCD8-apoA1 (acceptor) contained 921 pg VHHCD8-apoA1 . Big and small spheres with a 1 : 1 mix of donor and acceptor contained 513 pg apoA1-IL-2 and 467 pg VHHCD8-apoA1 .
• the aNPs in PBS were pipetted into a black 96 well plate (Thermo Fisher Scientific- Nunclon) at 100 pL per well.
• a 1 :1 mix (molar ratio) of fluorescently labeled apoA1-IL-2 and VHHCD8-apoA1 was included as control.
• the samples were excited at 520 nm and emission was detected between 560 and 780 nm with a step size of 5 nm in a Spark plate reader (T ecan). Data was normalized by dividing the intensity of one sample on each wavelength by the intensity of that sample at 565 (donor emission maximum).
• Example 6 Production, analysis, and evaluation of CD8+ T cell targeted apolipoprotein nanoparticles containing mRNA
• CD8-aNP-mRNA are prepared by rapid mixing through a T-junction mixer.
• the cationic ionizable lipid ALC-0315, dimyristoylfosfatidylcholine (DMPC), cholesterol, and tricaprylin are dissolved in ethanol at appropriate molar ratios (Table 2) to a final concentration of 10 mM total lipid.
• mRNA is dissolved in 25 mM sodium acetate buffer at pH 4.0 to obtain a final mixture with a defined nucleic acid to lipid weight/pmol ratio of 0.0278 (N/P 6).
• the organic and aqueous solutions are mixed at a flow ratio of 1 :3 (v:v) and a total flow rate of 28 mL/min.
• the resulting mixture is dialyzed against a 1000-fold volume of phosphate-buffered saline (PBS) pH 7.4 overnight.
• PBS phosphate-buffered saline
• the lipid nanoparticles containing mRNA and CD8VHH-apolipoprotein A1 fusion protein are mixed at a flow ratio of 1 :3 (v:v) and a total flow rate of 28 mL/min.
• the resulting CD8-aNP-mRNA are sterile filtered (0.2 pm) and concentrated using centrifugal flow filtration. Table 2.
• CD8-aNP-mRNA composition (molar ratios)
• CD8-aNP-mRNA are characterized according to size distribution by dynamic light scattering, zeta potential by laster doppler electrophoresis, mRNA encapsulation efficiency by Ribogreen assay, and cholesterol/phospholipid content using dedicated colorimetric assays.
• Spleens are obtained from mice, cut into pieces, and strained through a 70 pm strainer (Corning) multiple times to obtain a splenocyte suspension.
• Cells are spun down at 1500 rpm for 10 minutes, the supernatant is removed, and the cells are dissolved in 2 mL 1X red blood cell lysis buffer (Thermofisher).
• Cell suspension is incubated at room temperature for 5 minutes, 10 mL RPMI medium (Thermofisher) is added, and cells are again spun down at 1500 rpm for 10 minutes. Cells are then redissolved in RPMI medium and plated in a 96 wells plate at 150.000 cells/well.
• CD8-aNP-mRNA encoding for mCherry and controls formulations are added to the wells in appropriate concentrations and incubated for 6 hours 37 °C after which cells are harvested, washed, and stained for CD3 and CD4 and measured on Cytoflex (Beckman Coulter Inc.). Flow cytometry data is analyzed using FlowJo software (BD).
• CD8-aNP-mRNA encoding for mCherry and control formulations are intravenously injected in C57BL/6 mice at a dose of 0.5 mg/kg mRNA. After 6 hours, mice are sacrificed, blood is harvested and after PBS perfusion other tissues of interest (bone marrow, spleen, and lymph nodes) are harvested.
• the tissues are homogenized into a single cell suspension, stained for myeloid (CD115, F4/80, Ly6C, CD11 b, CD45, Ly6G, CD11c), lymphoid (CD45, CD11b, CD3, CD19, CD4, CD8a), and progenitor (CD117, CD34, Ly-6A/E, CD135, CD16/32, CD48, CD41 , CD150, CD3, CD11 b, CD45R/B220, Ly-76, Ly6G, Ly6C) cell markers, and analyzed on Cytoflex (Beckman Coulter Inc.). Flow cytometry data is analyzed using FlowJo software (BD). Results
• FIG. 12 The flow cytometry analysis of mouse splenocytes incubated ex vivo with apoA1 aNP, VHHCD8-apoA1 aNP, and VHHGFP-apoA1 aNP containing mRNA encoding for fluorescent mCherry protein is shown in Fig. 12 (left panel: CD3+ CD4- mCherry+ T cells, right panel: CD11 b+ mCherry+ myeloid cells).
• the results show that VHHCD8- apoA1 aNP induce functional mCherry reporter gene expression in significantly more CD3+ CD4- T cells when compared to apoA1 aNP, VHHGFP-apoA1 aNP and lipofectamine controls.
• ApoA1 aNP induce functional mCherry reporter gene expression in significantly more CD11 b+ myeloid cells when compared to VHHCD8-apoA1 aNP, VHHGFP-apoA1 aNP and lipofectamine controls. These results indicate that apoA1 aNP have a natural propensity to interact with myeloid cells, and that these aNPs can be rerouted to other immune cells (such as CD8+ T cells) by incorporating fusion proteins of apolipoproteins and targeting moieties.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Zoology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Biomedical Technology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biotechnology (AREA)
• Wood Science & Technology (AREA)
• General Engineering & Computer Science (AREA)
• Physics & Mathematics (AREA)
• Nanotechnology (AREA)
• Gastroenterology & Hepatology (AREA)
• Toxicology (AREA)
• Plant Pathology (AREA)
• Microbiology (AREA)
• Optics & Photonics (AREA)
• Cell Biology (AREA)
• Dispersion Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicinal Preparation (AREA)

Priority Applications (9)

Applications Claiming Priority (6)

Publications (1)

Family

ID=86424775

Family Applications (1)

Country Status (10)

Cited By (4)

Citations (3)

• 2023
  • 2023-05-24 KR KR1020247041349A patent/KR20250029793A/ko active Pending
  • 2023-05-24 AU AU2023277740A patent/AU2023277740A1/en active Pending
  • 2023-05-24 EP EP23724893.5A patent/EP4532026A1/en active Pending
  • 2023-05-24 WO PCT/EP2023/063967 patent/WO2023227682A1/en not_active Ceased
  • 2023-05-24 IL IL317201A patent/IL317201A/en unknown
  • 2023-05-24 CN CN202380042822.3A patent/CN119546627A/zh active Pending
  • 2023-05-24 US US18/865,898 patent/US20260041638A1/en active Pending
  • 2023-05-24 CA CA3254811A patent/CA3254811A1/en active Pending
  • 2023-05-24 JP JP2024569222A patent/JP2025519106A/ja active Pending
• 2024
  • 2024-11-19 MX MX2024014330A patent/MX2024014330A/es unknown

Patent Citations (3)

Non-Patent Citations (29)

Also Published As

Similar Documents

Legal Events